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Abstract
Analysis of somatic alterations in cancer genomes has been accelerated through the rapid
growth of the quantity, quality and depth of data generated by next-generation sequencing
(NGS). Previously most of cancer genome studies were focusing on single nucleotide varia-
tions (SNVs), small insertions and deletions (INDELs), or somatic copy number alterations
(SCNAs). Recently, there is a paradigm shift in the cancer genome study that more e↵orts
have been devoted to characterizing large scale structural variations (SVs) in various can-
cer genomes. However, there are still pressing needs for designing specific computational
algorithms to tackle the challenges caused by the complexity of cancer genomes.
The first part of my thesis is developing a novel computational method called Weaver,
which takes whole genome sequencing (WGS) alignment as core input and generates a precise
rearrangement map for cancer genomes. Weaver identifies SVs with base-pair resolution and
applies a probabilistic graphical model to simultaneously quantify allele specific copy number
of SVs (ASCNS) and genomic regions (ASCNG). Through evaluation on simulated datasets
with di↵erent parameter settings, Weaver was demonstrated to be highly accurate and be
able to significantly refine the analysis of complex cancer genomes.
The second part of this study is applying Weaver on two widely used cancer cell lines:
MCF-7 and HeLa. For both cell lines, we generated base-pair resolution ASCNS and AS-
CNG for the first time. The detailed characterization of genomes for MCF-7 and HeLa may
serve as valuable resource for future studies based on these two cell lines, by replacing ref-
erence genome with cancer specific genomes. We have found that allele specific expression
can be explained by the profiled ASCNG for both cell lines. We have also discovered that
a large portion of promoter-promoter interactions, detected by ChIA-PET, are found to be
formed by distal genomic regions linked to be adjacent by somatic translocations in MCF-7
genome, showing that phased SVs analysis by Weaver has enabled the analysis of interaction
between genomic rearrangements and long-range gene regulation at much broader scale.
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The last part of this thesis is applying Weaver on large-scale primary tumor data, com-
posed by 600 TGCA WGS samples. To our knowledge, this is the largest whole genome SV
and base-pair resolution ASCNG analysis for primary cancer genomes to date. We analyzed
two mechanisms, breakage-fusion-bridge (BFB) and tandem duplication (TD), for recurrent
focal amplifications and found di↵erent frequently focal amplified regions have di↵erent en-
richment of specific tumor types. We proposed a new pan-cancer classification method, for
the first time utilizing SV pattern, that categorizes 600 TCGA samples across 17 tumor
types into five subtypes with potential clinical relevance. Our pan-cancer classification has
the potential of prognostic assessment for future patients regardless of their tumor types.
In order to gain knowledge on the landscape of cancer genome structural alterations, in
this thesis, we developed an algorithm which handles WGS data and specifically tackles the
complexity in aneuploid cancer genomes. The integrative method combining the analysis
of SVs and SCNAs enabled novel findings when applied on cancer cell lines and primary
tumors.
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Chapter 1
Introduction
1.1 Cancer genome alterations
Cancer is a disease of genome responsible for one in four deaths in US and one in eight deaths
worldwide (Siegel et al., 2015). Precisely characterizing the genome alterations in cancer
genome serves as the very first step in the battle against cancer, which is one core part of the
recent Precision Medicine Initiative (Collins and Varmus, 2015). Indeed, one of the primary
incentives for the Human Genome Project (Lander et al., 2001) is to better understand
the genome of cancer (Dulbecco, 1986). The rapid development and wide application of
NGS have enabled unprecedented opportunity to characterize detailed alteration landscape
of cancer genomes.
The entire spectrum of somatic cancer genome alterations can be roughly divided into
two categories with di↵erent scales: i) Single nucleotide variations (SNVs) and small in-
sertions and deletions (INDELs), which are ‘local’ events mutating only one or a few base
pairs in genome; ii) SVs, including deletions, duplications, insertions, and rearrangements,
and genome aneuploidy, which are ‘global’ events modifying a large portion of or entire
chromosomes.
The SNVs landscape for di↵erent cancer types has been largely revealed by compre-
hensive sequencing e↵orts in recent years (Alexandrov et al., 2013; Kandoth et al., 2013;
Stratton, 2011). Pan-cancer analysis has also uncovered mutation signatures shared across
tumor origins (Ciriello et al., 2013; Hoadley et al., 2014). Mismatch repair deficiency and
specific mutagenic exposure, including smoking, UV light, and chemotherapy, have been
suggested to be the causal mechanisms of SNVs in certain specific tumor types (Greenman
et al., 2007; Lee et al., 2010; Pleasance et al., 2010a,b).
SNVs in cancer genome can be categorized as driver or passenger events (Vogelstein
et al., 2013). The first type is essential for tumor development and progression, especially
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core cellular processes including cell fate, cell survival and genome integrity (Vogelstein
et al., 2013), whereas the latter type has no selective advantage. Proper filtering of driver
events from ‘long-tail’ passenger events is critical in understanding the driving mechanisms
in tumorigenesis and selecting ‘actionable’ mutations as targets in clinical cancer treatment.
Recent studies showed that at least one ‘actionable’ alteration that might influence thera-
peutic decision-making or might suggest enrollment in a particular clinical trial have been
identified by matched tumor-normal sequencing in up to 76% of patients with various com-
mon solid tumors (Cancer Genome Atlas Research Network et al., 2012; Beltran et al., 2013;
Frampton et al., 2013; Jones et al., 2015). More importantly, with precise knowledge on the
catalogue of cancer genome ‘actionable’ mutations, it is now possible to design combination
therapies, which will be essential for cancer treatment since most tumors eventually de-
velop resistance to single-agent therapeutics because of redundancy of driver mutations and
complex genome heterogeneities (Garraway and Ja¨nne, 2012). With the decreasing cost,
genome sequencing is likely to become common practice in cancer treatments in the near
future (Frampton et al., 2013).
The study of cancer genome is currently in its first phase (Garraway and Lander, 2013),
which has been primarily focused on generating SNV catalogue in primary tumors. To fulfill
its full promise, it is necessary to deepen the structural characterization of cancer genomes.
Previous analysis on array data (Kononen et al., 1998; Moroni et al., 2005; Stratton et al.,
2009) and recent sequencing e↵orts (Stephens et al., 2009; Nik-Zainal et al., 2012; Cancer
Genome Atlas Research Network et al., 2011, 2012, 2013, 2014a,b, 2015) have shed light on
the SVs or SCNAs patterns across tumor types and revealed that SVs or SCNAs have critical
roles in activating oncogenes and in inactivating tumor suppressors. The understanding of
the biological and phenotypic e↵ects of cancer structural alterations has led to substantial
advances in cancer diagnostics and therapeutics (Tsao et al., 2005; Kim et al., 2008; Cheang
et al., 2009). However, our understanding of large scale SVs or aneuploidy in cancer genome
still remains limited, primarily due to the lack of specific computational algorithms to tackle
the challenges brought by the complexity of cancer genomes.
About 100 years ago, Theodore Boveri observed that genome aneuploidy, in which ab-
normal copy numbers of chromosome alleles are present, is a frequent feature of tumor cells
and suggested that it might represent a causal mechanism (Boveri, 1914). As in Figure 1,
copy numbers of most of MCF-7 chromosomes are not two. Recent studies have confirmed
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that aneuploidy, with either arm-level SCNAs or even whole-genome duplications, is one of
the most ubiquitous features of human cancer, present in greater than 90% of cases and a
hallmark of cancer (Gordon et al., 2012; Newburger et al., 2013; Weaver and Cleveland, 2006;
Torres et al., 2008; Beroukhim et al., 2010; Zack et al., 2013). Despite its ubiquity in cancer,
aneuploidy is not tolerated in normal human cells (Storchova and Pellman, 2004; Knouse
et al., 2014), implying that cancer specific alterations may confer viability to aneuploid
cells. SVs can further modify the aneuploid cancer genome into a mixture of rearranged
genomic segments with extensive range of SCNAs. Indeed, aneuploid cancer genomes have
significantly higher rate of SCNAs as well as SVs (Zack et al., 2013). A comprehensive and
precise characterization of these changes is crucial in understanding the evolution of cancer
genome (Greenman et al., 2012).
Several mechanisms of aneuploidy, or in general genetic instability, have been proposed,
including mutations in mitotic checkpoint genes that control chromosome segregation (Cahill
et al., 1998), and telomere crisis, whereby the normal telomeric ‘caps’ at the ends of chro-
mosomes erode to trigger DNA double-stranded break (DSB) response, which can result
in incorrect repairs between broken telomeres, leading to formation of dicentric chromo-
somes (Feldser et al., 2003). The state of dicentric chromosomes is not stable and cycles
of telomere crisis will be created. Indeed, a genomic focal amplification mechanism impor-
tant in shaping cancer genome, BFB, can be formed by the same telomere dysfunction (van
Steensel et al., 1998; Maser and DePinho, 2002; Romanov et al., 2001; Rudolph et al., 2001).
The detailed formation process of BFB is illustrated in Figure 2.
Historically, mutations in cancer genome are thought to accumulate through a gradual
process of mutation and selection over many cell division cycles, giving rise to an increase
in malignant phenotype over time (Hanahan and Weinberg, 2000; Helleday et al., 2014;
Yates and Campbell, 2012). In contrast to the progressive model of cancer genome struc-
tural aberration, in 2011, Stephens et al. (2011) proposed the ‘chromothripsis’ (chromo for
chromosome and thripsis for shattering) model, in which a single ‘catastrophic’ event leads
to large number of SVs (Figure 3). The two most commonly used evidence for identify-
ing chromothripsis is high density of SVs, with evenly distributed head/tail orientations,
and the oscillating copy numbers (Korbel and Campbell, 2013). The first article describ-
ing chromothripsis used SNP array copy number data of 746 cell lines and estimated that
chromothripsis is present at a low frequency (2-3%) of human cancers (Stephens et al.,
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2011). With WGS data, higher frequencies, especially in neuroepithelial tumors including
neuroblastoma (11%), medulloblastoma (13%), glioblastoma (39%) and melanoma (10%)
have been found (Molenaar et al., 2012; Malhotra et al., 2013; Kloosterman et al., 2014).
Studies in multiple myeloma, acute myeloid leukemia and melanoma showed a correlation
between chromothripsis and poor prognosis (Hirsch et al., 2013; Rausch et al., 2012a; Ma-
grangeas et al., 2011). Recent analysis has reported that across-sample copy number profile
on chr21 can be generated by recurrent chromothripsis in a specific subgroup of acute lym-
phoblastic leukemia patients (Li et al., 2014), suggesting that recurrent ASCNG profiles are
generated by recurrent chromothripsis. The mechanism for chromothripsis is unknown. One
experimentally untested hypothesis is that chromothripsis is generated by DNA replication
errors, in which collapsed replication forks trigger cycles of microhomology-mediated break-
induced replication and distal sequences are inserted to the sites of replication fork collapse
by template-switching (Liu et al., 2012, 2011). A recent study showed that DNA damage
in micronuclei might be one of the reasons leading to chromothripsis, by the fragmentation
and subsequent reassembly of a single chromatid from a micronucleus (Zhang et al., 2015).
1.2 Application of WGS in cancer genome analysis
With the rapidly decreasing sequencing price, non-coding regions serves as the new frontier
in cancer genome research with pressing need on advanced interpretation methods designed
for tackling challenges in cancer WGS. More than 98% of the human genome regions are
non-coding and considered as ‘dark matter’ in our understanding of cancer genome (Gar-
raway and Lander, 2013). It is known that most breakpoints of SVs are within non-coding
regions and may only be detected by WGS. To fulfill the ‘second phase’ of cancer genome
study (Garraway and Lander, 2013), which aims at understanding the detailed genome
wide rearrangement structures, it is important to generate more WGS data and to develop
analysis methods.
Besides revealing the catalogue of genome wide SVs, WGS can also be applied to reveal
mutational consequences on non-coding regions. Recurrent somatic mutations on promoter
region of TERT gene, encoding the catalytic subunit of telomerase, has been found in
multiple cancer types, including GBM and melanoma (Huang et al., 2013; Horn et al.,
2013). Recently these recurrent non-coding mutations are found to facilitate the selective
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binding of transcription factor GABP on TERT and activate its transcription (Bell et al.,
2015).
Whole genome analysis includes investigation on epigenetic features of cancer genome.
Epigenetic changes are commonly observed in tumor (Shen and Laird, 2013) and have been
revealed to play significant role in cancer. DNA hypermethylation in gene promoter regions
is a frequent event in cancer and can inversely correlate with gene expression (Jones and
Baylin, 2007; Shen and Laird, 2013). A recent study of colorectal cancer showed that more
than 10% of the protein-coding genes were di↵erentially methylated when compared with
normal epithelial cells (Beggs et al., 2013). It has been revealed that selective growth advan-
tages are generated by epigenetic changes (Jones and Baylin, 2007). For example, epigenetic
silencing of CDK2NA is more frequent than mutational inactivation in colorectal and lung
cancers (Beggs et al., 2013). Epigenetic data, especially DNA methylation alteration data,
is also included in TCGA datasets (Weisenberger, 2014). However, correct interpretation of
epigenetic data is depending on the precise cancer genome map (Adey et al., 2013), which
may only be delivered by deep WGS.
Equipped with integrative computational methods that simultaneously investigate multi-
ple features of cancer genome rearrangement, WGS provides the potential to add the missing
piece in our understanding of cancer genome and further facilitate systematic classification
of cancer genomes based on cellular mechanisms instead of tissue of origin. By testing
therapies on group of patients with similar genome aberrations, the comprehensive under-
standing of cancer genome might also substantially transform the design and interpretation
of clinical trials, accomplishing the promise of personalized medicine.
1.3 Contribution of the thesis
For cancer genomes, allele specific copy number of genome region (ASCNG) analysis meth-
ods have been developed for SNP array data (Wang et al., 2007; Van Loo et al., 2010; Carter
et al., 2012). Wang et al. (2007) applied hidden Markov model to detect kilobase-resolution
CNVs from Illumina high-density SNP genotyping data, utilizing total signal intensity and
allelic intensity ratio at each SNP marker, the distance between neighboring SNPs, the allele
frequency of SNPs, and the pedigree information where available. Van Loo et al. (2010) first
filtered noise of input array data and accurately dissected the allele-specific copy number
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of solid tumors, simultaneously estimating and adjusting for both tumor ploidy and non-
aberrant cell admixture. Carter et al. (2012) proposed to identify candidate tumor purity
and ploidy values and calculate their SCNA-fit log-likelihood scores, according to the ob-
served SNP array data, accomplished by fitting a Gaussian mixture model, and to estimate
the optimal sample purity and absolute ASCNG profiles.
Recently, ASCNG profiling methods for WGS data have also been developed (Mayrhofer
et al., 2013; Chen et al., 2014; Holt et al., 2013; Wang et al., 2015; Amarasinghe et al., 2014).
However, similar with methods developed for array, all these methods focus on partitioning
cancer genome into independent segments using coverage and allele frequency, under the
assumption that the information of breakpoint where copy number changes is unknown.
However, our analysis revealed high accordance between copy number change boundaries
and SV breakpoints (details in Chapter 4), demonstrating the potential advantage of
ASCNG identification coupled with SV detection.
Separately, several SV identification methods have been developed for WGS data (Chen
et al., 2009; Wang et al., 2011; Rausch et al., 2012b; Yang et al., 2013a). Chen et al. (2009)
used discordant paired-end reads to infer the existence of SVs with a rough estimation of
breakpoint boundaries. Wang et al. (2011) utilized ‘soft-clip’ (gapped alignment) information
in WGS alignment data and local assembly approach to detect exact SV boundaries. Rausch
et al. (2012b) combined short-range and long-range paired-end mapping and split-read anal-
ysis for the discovery of SVs at single nucleotide resolution. Despite the rapid development
of SV identification methods, we believe that SV identification is only the very first step in
analyzing cancer genome structural changes, and further information, including allele spe-
cific copy number of SVs (ASCNS), the phasing and the relative timing of SVs, are essential
to comprehensively understand SVs in cancer genomes. Chapter 2 presents a probabilistic
graphical model, Weaver, to simultaneously quantify ASCNG as well as ASCNS. Weaver is
the first integrative method that not only identifies SVs with base-pair resolution, but also
estimates the inter-connectivity of them in aneuploid cancer genomes. Through evaluation
on simulated datasets with di↵erent parameter settings, Weaver was demonstrated to be
highly accurate and be able to significantly refine the analysis of complex cancer genomes.
Cancer cell lines are widely used in all aspects of biology studies, with their underlying
genome largely unexplored. In Chapter 3, we analyzed deep WGS data for two widely
used cancer cell lines: MCF-7 and HeLa. We identified the high concordance between
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allelic expression with ASCNG. We have also discovered that a large portion of promoter-
promoter interactions, detected by ChIA-PET, are found to be formed by distal genomic
regions linked to be adjacent by somatic translocations in MCF-7 genome, showing that
phased SVs analysis by Weaver has enabled the analysis of interaction between genomic
rearrangements and long-range gene regulation at much broader scale.
To investigate the pan-cancer structural behavior on primary tumors, we downloaded
WGS data from 600 patients generated by TCGA and provided the most comprehensive
SV analysis to date in Chapter 4. We identified 47 clusters of SV breakpoints in the
pan-cancer analysis, with 12 and 23 of them are focal deletion and amplification hotspots,
while the remaining breakpoint clusters are enriched with translocations. We analyzed
two mechanisms, BFB and TD, for 17 recurrent focal amplifications and found di↵erent
frequently focal amplified regions have di↵erent enrichment of specific tumor types. We
proposed a new pan-cancer classification method, for the first time utilizing SV pattern, that
categorizes 600 TCGA samples across 17 tumor types into five subtypes with significantly
di↵erent survival.
Finally in Chapter 5, we provide a brief summary of this thesis, its limitations and
directions of future work.
1.4 Figures and Tables
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Figure 1: Multi-color FISH karyotype of MCF-7 cell line, showing a typical example of
aneuploid cancer genome. For example, MCF-7 genome has six copies of chromosome 14,
instead of two. Chromosomes shown by more than one color indicate the existence of INTER
chromosomal SVs. Figure was obtained from Rondo´n-Lagos et al. (2014).
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Figure 2: Genomic amplification by BFB cycles. (a) Normal chromosome protected by
telomeres (indicated by the red box) (b) Telomere loss creates an unprotected DNA end
(‘breakage’), which triggers a DNA damage response. (c) Cancer cells with checkpoint
defects will continue to grow despite DNA damage signaling, leading to the duplication of
the broken chromosome. (d) Broken chromatid ends are unstable and the ‘fusion’ between
them produces a ‘bridge’ connection between the two sister chromatids. (e-f) Bi-centric
chromosome is unstable and the ‘bridge’ will break as centromeres are pulled to opposite
poles of the dividing nucleus. Further BFB cycles (b-f) will continue, leading to the dramatic
amplification of genomic regions, potentially containing oncogenes (indicated by the blue
box). Figure was converted from Bunting and Nussenzweig (2013).
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Figure 3: Overview of chromothripsis. In a catastrophic event, original genome was shat-
tered into DNA fragments, the subsequent random repair of DNA fragments leads to chro-
mosomal rearrangements, as well as the loss of some genomic regions. Figure was obtained
from Tubio and Estivill (2011).
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Chapter 2
Allele-specific quantification of
SVs in cancer genomes
2.1 Introduction
Existing WGS ASCNG methods utilize a variety of signals to make copy number calls,
including read-pair, split-read, read-depth or allele-specific information (Mills et al., 2011;
Abecasis et al., 2012; Medvedev et al., 2010). For cancer studies, tumor/normal sample
pairs may also be used for noise correction. All these methods focus on partitioning cancer
genome into segments using coverage and allele frequency, under the assumption that the
information of breakpoint where copy number changes is unknown. However, a recent
analysis revealed that many copy number change boundaries are on SV breakpoints (Li
et al., 2014), demonstrating the potential advantage of ASCNG identification coupled with
SV detection. Separately, many SV identification methods have been developed for WGS
data (Chen et al., 2009; Wang et al., 2011; Rausch et al., 2012b; Yang et al., 2013a). We
believe SV identification is only the very first step in analyzing cancer genome structural
changes. Further information, including allele specific copy number of SVs (ASCNS), the
phasing and the relative timing of SVs, are essential to comprehensively understand SVs in
cancer genomes.
It is essential to ask how SVs interact with ASCNG and how di↵erent SVs interact with
each other. The answers to such questions can help unravel the detailed cancer genome
structure and its evolutionary history. However, no integrative method specifically designed
for simultaneously analyzing SVs and ASCNG has been developed. Indeed, except arm-
level gain/loss, the majority of SCNAs are associated with SVs (Li et al., 2014). It has been
recently reported that analyzing copy number pattern around SV breakpoints can reveal
the mutational forces causing particular cancer subtype (Li et al., 2014). Moreover, the
integrated approach can further assist the variants phasing in di↵erent scales (both SNPs
and SVs) in the context of complex cancer genome architecture.
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To address the problem, we developed a novel computational method Weaver to identify
allele specific copy number of SVs (ASCNS) as well as the inter-connectivity of them in
aneuploid cancer genomes. Under the same method framework, Weaver also provides base-
pair resolution ASCNG. We first search SVs based on NGS reads at base-pair resolution
and build cancer genome graph, which is subsequently converted to a pair-wise Markov
random field (MRF). In the MRF, the ASCNS and SV phasing configuration, together with
genomic ASCNG, are hidden states in nodes and the observations contain all sequencing
information, including coverage, read linkage between SNPs as well as between SV and
SNPs. Therefore, our goal of finding the ASCNS and SV phasing together with ASCNG
is formulated as searching the maximum a posteriori (MAP) solution for MRF. We apply
Loopy Belief Propagation (LBP) framework to solve the problem.
Being a SV-centric integrative graphical model which well fits the complex nature of
cancer genomes with reorganized chromosomes, Weaver’s novel contribution is tri-fold: (i)
The method provides, for the first time, a quantitative measurement of copy number of SVs
in cancer genome; (ii) It estimates, for the first time, the phasing/linkage information of
di↵erent SVs using NGS data; (iii) The method generates, for the first time, the highly ac-
curate base-pair resolution (note that all previous methods can only provide rough estimate
of SCNA boundaries, as in Figure 6) ASCNG profiling in aneuploid cancer genomes, by
simultaneously achieving (i) and (ii). Our simulation evaluation and real data application
(MCF-7 and HeLa in Chapter 3; TCGA pan-cancer datasets in Chapter 4) demonstrated
that Weaver is highly accurate and can significantly refine the analysis of complex cancer
genomes.
2.2 Methods
The overview of the Weaver algorithm is shown in Figure 4. The input of Weaver is
the BAM file of aligned and unaligned reads from a particular tumor sample. If there is
matched normal sample available, it will also be used (details in Section 2.2.5). The first
step is to call variants (including both SNPs and SVs) based on the BAM file. The detailed
description for preparing Weaver input is in Section 2.2.1. Using the intermediate results
(yellow boxes in Figure 4) including the cancer genome graph construction (Section 2.2.3),
the Weaver MRF model will be built. By solving the MRF MAP function (Equation 2.4),
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Weaver generates output as in the green boxes in Figure 4 (see Figure 7(E) for example).
The core modules in Weaver were written in C++. Weaver source code is freely available
and can be downloaded from: http://bioen-compbio.bioen.illinois.edu/weaver/.
2.2.1 Preparing the input of Weaver
As illustrated in Figure 4, all sample-dependent input of Weaver is just the tumor sample
alignment file (normal alignment file is another input if available), the direct inputs of
Weaver MRF model are generated by the following approaches:
Alignment and SNP calling
All NGS data alignment was done by BWA (version 0.7.4) (Li and Durbin, 2009), with
default parameter settings. SAMtools (version 0.1.19) (Li et al., 2009) is used to call SNP.
In order to infer ASCNG, as well as the phasing of SNPs, we only retain SNPs from original
SNP list from samtools with following criteria: i) being heterogenous ii) not in segmental
duplications; iii) mappability > 0.2; iv) reported in 1000 Genomes Project; v) if normal
counterpart is also sequenced, SNP needs to be found in the normal sample (germline).
Overall, 1,507,969 SNPs are retained in MCF-7 dataset. These germline polymorphic sites
are used to infer ASCNG, and serving as informative targets in haplotype phasing.
SNP linkage from NGS
We assume that if two SNPs are found on one NGS read (or read pairs), they are likely
from the same allele. The method to calculate SNP linkage from NGS is in Equation 2.2.
SNP linkage from 1000 Genomes Project
1000 Genomes Project Phase 1 release (Abecasis et al., 2012) has provided the haplotype
phased 1092 individuals, with which linkage disequilibrium (LD) can be calculated for ad-
jacent SNPs. The method to calculate SNP linkage from 1KGP is in Equation 2.1.
2.2.2 SV identification
Although the main focus of Weaver is not on SV finding, the inconsistency between current
SV detection tools motivated us to develop an SV finding procedure to reliably detect SV
with base-pair resolution, with two strategies together:
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1. Discordant paired-end clusters: When mapping paired-end NGS reads onto the refer-
ence genome, the reads mapped to smaller coordinates are expected to be on forward
strand, while their paired-end partners are on reverse strand. The presence of abnor-
mal paired-end mappings, either from unexpected insert size or mapping orientation,
is indication of SVs. We cluster all abnormal paired-end mappings by their mapping
positions and only clusters with at least four read-pairs are retained, denoted as P.
2. Soft-clip mapping clusters: Some NGS alignment programs, such as BWA (Li and
Durbin, 2009), will search for local alignment (soft-clip) when they failed to find
confident alignment for the entire read. Many of those soft-clipped reads may be
spanning across SV breakpoints. The ‘clipped’ part of those reads can in fact be split
from the original read and then re-aligned to other side of breakpoints, revealing base-
pair resolution breakpoints, similar with Wang et al. (2011); Rausch et al. (2012b).
We cluster these split alignments by their coordinates. Only the clusters with at least
four split-read are retained, denoted as S.
We combine the clusters from both P and S to get highly reliable SVs, which are
supported by both discordant mappings and breakpoint spanning reads. However, some
SVs are small in scale or proximal to each other, making it extremely di cult to detect
them through P. Also, some other SVs have undergone mutations around breakpoints and
it is di cult to recognize them to base-pair resolution through S approach. We also retain
SVs supported by only one cluster, either P or S, with higher read number cut-o↵s (we use
10 in this work). The final SV set is C := PTSS {x : x 2 P \ SSS \ P , N(x) > 10}. For
simplicity, we use C to represent the set of SVs, as well as the set of SV nodes in MRF.
To filter out potential false positives, we further screen C using the following steps:
1. We pull out two flanking genomic regions on both sides of a combined cluster and map
them independently back to the reference genome. We only retain SVs inferred from
clusters with flanking regions uniquely mapped, filtering out potential false positives
caused by read mapping ambiguity.
2. We scan the mappability score around both breakpoints of SV. If the average score of
one breakpoint is less than 0.1, the SV will be discarded.
3. For long range SVs, we observed that some false positive SVs are in fact germline
segmental duplications (stretches of DNA that are at least 1kb in length and share a
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sequence identity of at least 90% (Bailey et al., 2001)), if two breakpoints of SV are
within the paired regions of segmental duplications, the SV will be discarded.
The final list of SVs from the tumor sample is reported in VCF format. The output
of Weaver SV finding pipeline is SV list C with linkage information to adjacent SNPs (if
within range of NGS read pairs), which is used to assist SV phasing (see Section 2.2.10).
We further screen our SV list using germline SV database DGV (MacDonald et al., 2014)
as well as SVs called from normal sample if available, when the overlap is >90%.
2.2.3 Genome partitioning and Cancer Genome Graph
construction
We first select a default size W (e.g., 5kb) and partition the genome into non-overlapping
regions as follows: (i) Breakpoints in SV set C must be on region boundaries; (ii) Each
region may contain no more than one SNP; (iii) The size of each region must be W . The
number of regions from initial segmentation ranges from 1.7 million to 2 million from Weaver
based on various datasets, depending on the size of loss of heterozygosity (LOH) regions
and the number of SVs. The rationale behind the segmentation step with SVs is that it is
known that most of the time (82.3% from TCGA analysis, details in Section 4.3.1) ASCNG
boundaries coincide with SV breakpoints (Li et al., 2014). Our segmentation approach using
SV boundaries has the advantage to provide base-level ASCNG boundaries as compared to
existing genome segmentation methods in copy number analysis, which typically use fixed
segmentation size.
Given the segmentation of the genome and SV set C, we then build Cancer Genome
Graph G := {R, E} (Figure 7(B)), with nodes representing genomic region sets (R) and
edges representing reference adjacencies (Er) (solid lines in the figure) if two nodes are
adjacent in the normal genome and cancer adjacencies (Ec) (dashed lines in the figure) if
two nodes are adjacent in the cancer genome by SV c linkage. Edge configurations E between
node Ri and Rj can be represented as: ( iRi ⇠  jRj),   2 {+, }, with + and  representing
the tail (right) and head (left) of a given genomic region R, e.g., (+Ri ⇠  Ri+1) 2 Er, if
Ri and Ri+1 are adjacent regions from the same chromosome in the normal genome.
We then convert the original Cancer Genome Graph G := {R, E} into MRF (M :=
{R,Rc, Er, Ec}), which is a widely used probabilistic graphical model to estimate joint
probabilities (details in Section 2.2.6). The MRF can be viewed as undirected graph and
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the aggregated inference problem in Weaver given sequencing data can be viewed as a
maximum a posteriori (MAP) problem with hidden states and observations explained in
the following sections. Unlike conventional methods for estimating copy number changes
based on hidden Markov models (HMMs), which are designed for sequential data and only
consider the dependencies between ‘local’ variables, MAP solution of MRF model provides
the most probable configuration of aneuploid cancer genomes with complex SVs, involving
‘global’ variable dependencies defined by long-range SVs. The detailed steps are described
in Section 2.2.6. In the following sections, we describe hidden states, observations, and
formal function of the MRF MAP problem.
2.2.4 Hidden states H
For ith genome node Ri 2 R ⇢ M, the hidden states are Hi={Cai ,Cbi , Gai , Gbi}, where
Cai = {Cai,0, ..., Cai,K} and Cbi = {Cbi,0, ..., Cbi,K} are vectors of non-negative integral numbers
representing copy numbers (CNs) for allele a and b of kth population on Ri, respectively.
When k = 0, it stands for the fraction of normal cells. Note that although the Weaver
algorithm is generic and in principle can be applied for multiple subclones (K > 1), in our
current implementation, Weaver only processes tumor samples without significant subclonal
structure (i.e., K = 1; if the coverage of estimated tumor genome >15X and the goodness
of fit is higher than  30). We leave the cases for K > 1 as future work. Gai and Gbi
represent the genotype of allele a and b of Ri, which is independent from subclone structure
since only germline SNPs are considered. For convenience, we also set variable Ci,k as the
overall copy number of kth population on Ri (Ci,k = Cai,k +C
b
i,k). In our analysis of cancer
genomes, which typically have highly amplified regions, we do not have limit for Ci,k, as
done by previous SCNA methods. The hidden copy number is bounded by the observation
of sequencing depth on each region. Note that for regions with low mappability or extreme
GC content, it is not reliable to infer hidden state space with observed local sequencing
coverage; instead, we search the closest region and inherit its hidden state space setting,
assuming that there is no dramatic state change between them.
The hidden states on cancer nodes Rc are discussed in Section 2.2.10.
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2.2.5 Observations O
For observation on R ⇢ M, on ith genomic region Ri 2 R, the observation from the
hidden state is the raw read coverage Oi on entire Ri, which can be estimated by BED-
Tools (Quinlan and Hall, 2010) based on BAM file. For tumor sample with matched nor-
mal genome sequenced, we calculate ONormi for the same Ri and normalize the Oi using:
Onewi = O
Norm ⇥ Oi/ONormi , where ONorm is the median coverage for all regions in the
normal genome.
If Ri has SNP, Oai and O
b
i are the number of reads containing the SNP based on a/b
allele, respectively, which can be obtained from SNP calling pipelines such as (Li, 2011). In
practice, neither sequencing nor mapping is uniform across the genome. Here we consider
two widely used factors, the GC-content and short read mappability. Using two HapMap
samples NA18507 and NA12878, we split the human genome into consecutive 100bp bins
and calculated the average mapping coverage on each bin. Among the bins that have
unexpected low or high coverage as compared to the rest of the genome, more than 91%
have either mappability < 0.6 or GC-content < 0.2 or > 0.6. Therefore, we label all Ri as
not read-depth informative, if mappability < 0.6 or GC-content < 0.2 or > 0.6. The read
depth of those uninformative regions are assigned from their closest informative regions.
Regarding observation on Er ⇢M, within two adjacent genomic regions Ri, Ri+1 2 R,
there are two independent observations for their genotype linkage.
(i) We assume the genotypes on i and i+1 are Gai /G
b
i and G
a
i+1/G
b
i+1, respectively. We
define the Linkage Disequilibrium (LD) score for the phasing configurationGai , G
a
i+1/G
b
i , G
b
i+1
as:
LD(Gai , G
a
i+1/G
b
i , G
b
i+1)
=
NLD(Gai , G
a
i+1)⇥NLD(Gbi , Gbi+1)
NLD(Gai , G
a
i+1)⇥NLD(Gbi , Gbi+1) +NLD(Gai , Gbi+1)⇥NLD(Gbi , Gai+1)
(2.1)
where NLD(Gai , G
a
i+1) is the number of phased haplotypes (total number 1092⇥ 2 in phase
1) in 1KGP with genotype (Gai , G
a
i+1). Other genotype configurations can be similarly
calculated.
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(ii) Similarly, we define the read linkage score for the phasing Gai , G
a
i+1/G
b
i , G
b
i+1 as:
RL(Gai , G
a
i+1/G
b
i , G
b
i+1) =
NRL(Gai , G
a
i+1) +NRL(G
b
i , G
b
i+1)
NRL(Ri, Ri+1)
(2.2)
where NRL(Ri, Ri+1) is the total number of reads covering genomic regions (Ri, Ri+1) and
NRL(Gai , G
a
i+1) is total number of reads covering (G
a
i , G
a
i+1). If there are no reads covering
(Ri, Ri+1) (NRL(i, i+ 1) = 0), RL = 0.
Therefore, we define genotype linkage as
GL(Gai , G
a
i+1/G
b
i , G
b
i+1) = log(LD(G
a
i , G
a
i+1/G
b
i , G
b
i+1)⇥RL(Gai , Gai+1/Gbi , Gbi+1)) (2.3)
In real data application, we have found that RL and LD correlate very well. For example,
in the MCF-7 analysis, when we chose SNP pairs with 100% RL support as gold standard,
we found AUC= 0.9964 using LD scores.
2.2.6 Converting Cancer Genome Graph to MRF representation
We convert the original Cancer Genome Graph G = (R, E) into MRF (M) with the following
steps (see Figure 7(C) for example):
1. Nodes R in G are inherited as genome nodes in M, with potential function described
in Equation 2.7 and 2.8. We still use R to represent the set of genome nodes in M.
2. Reference adjacency (+Ri ⇠  Ri+1) without cancer breakpoints (+Ri 62 Ec,  Ri+1 62
Ec) are inherited in MRF as genome edge. For example in Figure 7 (C), (+R3 ⇠
 R4) is retained from G to M, while (+R6 ⇠  R7) in G is not included in M since
+R6 2 n := (+R6 ⇠  R10) . The pairwise potential function for newly connected
nodes in MRF is provided in Section 2.2.11. We use Er as set of genome edges in M.
3. For each cancer adjacency Ec := ( iRi ⇠  jRj),   2 {+, }. All reference adjacencies
in G linking Ri, Ri+ i1 and Rj ,Rj+ j1 are deleted and a cancer node Rc is added.
The potential function for Rc, is provided in Section 2.2.10. For example in Figure 7
(C), the edges (+R6 ⇠  R7) and (+R9 ⇠  R10) in G are deleted and a new node Rn
is added in MRF. We use Rc as the set of cancer nodes in M.
4. Cancer node Rc connects to genome nodes Ri, Ri+ i1, Rj and Rj+ j1 by adding cancer
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edges in MRF. For example in Figure 7(C), the R6, R7 and R9, R10 connect to Rn.
We use Ec as the set of cancer edges in M.
We denote the MRF as M := {R,Rc, Er, Ec}.
2.2.7 MRF model M
After we convert G into MRF M using steps in Section 2.2.6, the MRF MAP problem is
given by:
Hˆ = argmaxH
(X
i2R
⇥R(O|Hi) +
X
c2C
⇥C(O|Hc)
+
X
i2R
 R(O|Hi, Hi+1) +
X
c2C
X
i2N (c)
 C(Hi, Hc)
9=;
(2.4)
where ⇥R(O|Hi) is the genome node (green box in Figure 7(C), Section 2.2.8) potential
function. ⇥C(O|Hc) denotes constraint function in cancer nodes (red box in Figure 7(C),
Section 2.2.10).  R(O|Hi, Hi+1) is the genome edge (link between green boxes in Fig-
ure 7(C), Section 2.2.9) function, providing pairwise constraints of hidden states of neigh-
boring genome nodes Ri, Ri+1.  C(Hi, Hc) is the cancer edge (link between green and red
box in Figure 7(C), Section 2.2.11) potential function. N (c) stands for the index of
genome nodes linked to SV c.
The general MRF MAP problem is computationally intractable (Shimony, 1994). Sev-
eral approximation approaches have been proposed to solve this problem (Boykov et al.,
1998; Li, 2012; Anguelov et al., 2005). Here we utilize Belief Propagation (BP) to solve the
MRF MAP problem. BP was originally proposed for graphs without cycle (Pearl, 1988),
in which case the fixed point of max-product belief propagation algorithm is also the as-
signment of MAP (Weiss and Freeman, 2001). When applying on graph with arbitrary
topology, the Loopy Belief Propagation (LBP) can still approximate well to the MAP con-
figuration (Frey and MacKay, 1998). With Hˆ estimated, the Hˆi on genome node provides
base-pair resolution ASCNG and Hˆc on cancer node provides estimation of ASCNS.
We use LBP to find the exact/approximate MAP configuration of MRF. The message
updating rule from node Rj to node Ri (as illustrated in Figure 7(D)) at (t+1)th iteration
19
is:
m(t+1)j!i (Hi) / maxHj
8<: R(Hj , Hi) + ⇥R(Hj) + X
s2N (j)\i
m(t)s!j(Hj)
9=; (2.5)
where N (j) \ i stands for index of all the nodes linked to node j, except for node i. Note
that the max-product form of message passing is used to get state configuration with MAP.
The above function assumes Ri and Rj are genome nodes, corresponding potential will be
replaced if Ri or Rj is cancer node.
The belief vector (max-marginal) is computed for each node at tth iteration:
b(t)i (Hi) = ⇥R(Hi) +
X
j2N (i)
m(t)j!i(Hi) (2.6)
If convergence (b(T )i (Hi) = b
(T 1)
i (Hi)) or the maximum iteration number is reached at T
th
iteration, the final belief vector for each node is b(T )i (Hi). The set of Hˆ that provides the
largest belief: b(T )i (Hˆi) = max(b
(T )
i (Hi)) will be the MAP result for our problem. Since the
message passing in BP is proportional to the number of nodes, we reduce the number of
nodes with the procedure described in Section 2.2.12.
As illustrated in Figure 7(E), the final output of Weaver has three major parts: (i) the
purity (µ0 and µ1) and haplotype level coverage b (details in Section 2.2.8); (ii) ASCNG; (iii)
ASCNS, as well as the timing of SVs with respect to chromosome amplification or deletion
(aneuploid).
2.2.8 Genome node potential function ⇥R(O|Hi) and parameter
⇥ˆR estimation
⇥R(O|Hi) is the log-potential function providing constraints for each node Ri. Empirically
the distribution of read coverage on chromosomal regions with identical copy number follows
Poisson distribution (dispersion   = 1). Due to various source of variations in sequencing as
well as alignment, Negative Binomial (NB) model has been proposed to consider the over-
dispersion (  > 1) (Robinson and Smyth, 2008). With the observation in cancer genome
from extensive focal amplifications arisen from various mechanisms including BFB cycle, we
set no limit on the size of state space (i.e., total CN) in our model. Our model is based on
the assumption that the mean coverage of a genomic region is proportional to its CN. We
set µ as the vector storing the fraction of normal and tumor subclone cells, b as the base
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coverage on each haplotype,   as dispersion parameter of NB distribution, thus parameter
set for genome node potential function is ⇥R = { , b, µ}.
For Ri without SNP,
⇥R(O|Hi) = logNB(Oi|
X
k
µkCi,kb, ) (2.7)
For Ri with SNP,
⇥R(O|Hi) = logNB(Oai |
X
k
µkC
a
i,kb, ) + logNB(O
b
i |
X
k
µkC
b
i,kb, ) (2.8)
where
NB(y|x, ) =  (y +  
 1)
 (  1) (y + 1)
✓
1
1 + x 
◆  1 ✓ x
x+   1
◆y
(2.9)
X
k
µk = 1 (2.10)
x denotes the expected mean coverage based on copy number and base coverage.  denotes
the dispersion. y denotes the observed number of reads mapped to the given region Ri.
Unlike copy number variation analysis in normal genomes, the unknown degree of ane-
uploidy and level of normal contamination in cancer sequencing data makes the estimation
of single chromosomal coverage challenging. Initial partition of the genome by SVs in
Weaver leads to continuous genomic regions with start and end points defined by two SV
breakpoints. Although we assume that most of copy number changes have corresponding
breakpoints and can be detected by reads, some partitioned regions will still have copy
number change (breakpoint missed by SV identification method) and not suitable for dis-
persity estimation. We estimate the parameters ⇥ˆR = (bˆ,  ˆ, µˆ) from high confidence regions
S with sampling   < 3 and size > 1Mb. Within each continuous region Si, the hidden
ASCNG state Hi (Cai,k and C
b
i,k) is identical. Given our sequencing data, we can calculate
the posterior distribution using Bayesian methods, with prior information on ASCNG of Si,
P (Ci):
P (Ci) =
8>>>><>>>>:
0, if Cbi,0 6= 1 _ Cai,0 6= 1
0.1t, else if Ci,1   4
t, else
(2.11)
We set µ0 as normal cell fraction, thus Cai,0 and C
b
i,0 must be 1. Since in current Weaver
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implementation, we set k < 2, Ci,1 stands for copy number of tumor sample. Knowing
that ultra-hyperploid copy number is rare, penalty factor (0.1) is imposed on   4 CNs (the
frequency of regions with allelic copy number   4 is < 5% (Figure 45)). The exact value
of parameter t has no impact on ⇥ˆR estimation. The parameters can be estimated via:
⇥ˆR = argmax⇥RL(⇥R|S)
L(⇥R|S) = P (S|⇥R)P (⇥R)
P (S) / P (S|⇥R)
=
Y
i2S
Y
Rj2Si
P (Oj |b, , µ)
=
Y
i2S
Y
Rj2Si
X
Ci
P (Oj ,Ci|b, , µ)P (Ci)
=
Y
i2S
Y
Rj2Si
(X
Ci
NB(Oaj |
X
k
µkC
a
i,kb, )NB(O
b
j |
X
k
µkC
b
i,kb, )P (Ci)
)
(2.12)
L(⇥R|S) models the likelihood of parameter set ⇥R = { , b, µ} when observing S.
We numerically estimate (i.e., enumerating all discrete nodes within parameter space
lattice, with fixed step size) the posterior distribution and estimate the Bayesian credible
interval for the MAP parameters (Figure 9). We also evaluated Weaver on simulated data
with respect to purity estimation of the tumor. The results are plotted in Figure 11. With
various normal cell fraction µ0, Weaver precisely reported µ0, with R2 = 0.998.
2.2.9 Genome edge potential function  R(O|Hi, Hi+1)
Genome edge potential function  R(Hi, Hi+1) provides constraints on the node set Ri, Ri+1:
 R(O|Hi, Hi+1) =   log
X
k
 |Cai,k   Cai+1,k|+ |Cbi,k   Cbi+1,k| +GL(Gai , Gai+1/Gbi , Gbi+1)
(2.13)
The term   models the penalty of ASCNG change between Ri and Ri+1. The hidden
ASCNG between two adjacent genome nodes stays the same for most of the regions and
only changes under two conditions: i) One of the two nodes is linked to telomere of derived
cancer chromosome; ii) A breakpoint from SV undetected by initial SV detection method
resides between the two nodes. Both of these scenarios are rare, except for the case of
centromeres, when chromosome arm level amplification or loss happened. SVs happened
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inside centromeres are also extremely hard to detect because of the repetitive nature of
centromere sequences. We set   between two genome nodes flanking the centromere lower
than   between other nodes since copy number changes are much more likely to happen
within centromere regions than any other specific region (Carter et al., 2012).
2.2.10 Cancer node potential function ⇥C(O|Hc)
For cancer node Rc, we set the involved SV c with index: ( iRi ⇠  jRj),   2 {+, }. Thus
Rc :=
 
Ri, Ri+ i1, Rj , Rj+ j1
 
. The potential function for cancer nodes Rc is defined as
follows. Without loss of generality, we name two alleles on each SV involved chromosome
as a and b, and we assume SV c is on allele a. We use Cc as the hidden copy number of SV.
1. If c is INTRA chromosomal that Ri and Rj are on the same chromosome, there are
two possible constraints: i) SV c stems from single allele (heterozygous) and it might
be either germline or somatic. ii) c stems from both alleles (homozygous) and it must
be germline (one somatic SV is rarely to independently occur on both a and b alleles,
with the same genomic coordinates), we set range limit L as 1Mb (very large germline
SVs are rare (Mills et al., 2011)) for germline SVs. Under our assumption, if SV is on
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both a and b alleles, it must be on all copies of a and b alleles.
⇥C(O|Hc)
= GL(Gai , G
a
i+ i1/G
b
i , G
b
i+ i1) +GL(G
a
j , G
a
j+ j1/G
b
j , G
b
j+ j1)
+RLSV (G
a
i , c) +RLSV (G
a
j , c)
+
8>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>><>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>:
⇡(Cc,k, Cai,k)
+⇡(Cc,k, Caj,k)
somatic SV if
8>>>><>>>>:
Cai,k   Cai+ i1,k = Caj,k   Caj+ j1,k = Cc,k
Cbi,k   Cbi+ i1,k = Cbj,k   Cbj+ j1,k = 0
k ✓ {1, ...,K} that Cc,k > 0
Pgerm del
+RLSV (Gbi , c)
+RLSV (Gbj , c)
germline del if
8>>>>>>>>>>>>>>>>><>>>>>>>>>>>>>>>>>:
Dist(Ri, Rj) < L
 i = +,  j =  
Cai+ i1,k = C
a
j+ j1,k
= 0
Cbi+ i1,k = C
b
j+ j1,k
= 0
Cai,k = C
a
j,k > 0
Cbi,k = C
b
j,k > 0
Cc,k = Cai,k + C
b
i,k > 0
Pgerm dup
+RLSV (Gbi , c)
+RLSV (Gbj , c)
germline dup if
8>>>>>>>>>>>>>>>>>><>>>>>>>>>>>>>>>>>>:
Dist(Ri, Rj) < L
 i =  ,  j = +
Cai+ i1,k = C
a
j+ j1,k
> 0
Cbi+ i1,k = C
b
j+ j1,k
> 0
Cai,k
Cai+ i1,k
=
Caj,k
Caj+ j1,k
2 Z
Cbi,k
Cbi+ i1,k
=
Cbj,k
Cbj+ j1,k
2 Z
Cc,k = Cai,k + C
b
i,k   Cai+ i1,k   Cbi+ i1,k
 1 else
(2.14)
RLSV (G
a
i , c) =
8><>: 1 if c supporting NGS reads covering genotype G
a
i
0 else
(2.15)
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⇡(Cc, C
a
i ) =
8>>>><>>>>:
⇡1 if Cai = Cc = 1
⇡2 if Cai,k = Cc,k > 1
⇡3 if Cai,k > Cc,k   1
(2.16)
For example, in Figure 7(A), the dashed line linking the tail of R6 and head of R10
can be presented as SV n := (+R6 ⇠  R10), which is likely to be a deletion of region
[R7, R9]. For this n, we have cancer node Rn which is a supernode with R6, R7, R9, R10
(Figure 8) and it is straightforward to discard potential hidden states that lead to
|(C6   C7)   (C10   C9)| > 0 (allele information is omitted), which describes the
inconsistency of inferred total copy number of SV n.
k is the set of subclones that c is on. ⇡1 represents the prior probability of a SV with-
out timing information; ⇡2 represents the prior probability of a pre-aneuploidy SV
which has been amplified; ⇡3 represents the prior probability of a post-aneuploid SV,
as Del1 and Del2 are both post-aneuploid deletions with copy number one and two,
which are less than the copy number three of the amplified allele in MCF-7 genome
Figure 22. We assume ⇡1 ⇡ ⇡2 ⇡ ⇡3   Pgerm del ⇡ Pgerm dup.
2. If c is INTER chromosomal that Ri and Rj are on di↵erent chromosomes (non-
homologous), SV c is not possible to be germline, thus SV c is not possible to be
on both a and b alleles. WLOG, we still name two alleles on each SV involved chro-
mosome as a and b, and we expect SV c is on allele a.
⇥C(O|Hc) = GL(Gai , Gai+ i1/Gbi , Gbi+ i1) +GL(Gaj , Gaj+ j1/Gbj , Gbj+ j1)
+RLSV (G
a
i , c) +RLSV (G
a
j , c)
+
8>>>><>>>>:
⇡(Cc, Cai ) if
8><>: C
a
i   Cai+ i1 = Caj   Caj+ j1 = Cc
Cbi   Cbi+ i1 = Cbj   Cbj+ j1 = 0
 1 otherwise
(2.17)
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2.2.11 Cancer edge potential function  C(Hc, Hi)
For i 2 N (c), the pairwise potential function on cancer edge (Rc, Ri) is:
 C(Hc, Hi) =
8><>: s if Hi 6= H
0
i
1  s if Hi = H 0i
(2.18)
The parameter s is small (0.01 in current version of Weaver) and models the penalty of copy
number inconsistency between SV and involved genomic regions.
2.2.12 Reducing node numbers in MRF
We reduce the number of nodes in original M to speed up the computation procedure
described in Equation 2.5. For each chain of genome nodes R⇢, (⇢ := {n, n + 1, ...,m},
m > n) with deg(R⇢) = 2, Rn links to cancer node Rt and Rm links to cancer node Rs.
We replace all nodes in ⇢ with a supernode R(n,m), which is the Cartesian product of Rn
and Rm, |R(n,m)| = |Rn|⇥ |Rm|. As illustrated in Figure 7(C), node chains which can be
clustered as supernode are shaded in light blue. For convenience, we denote all remaining
nodes other than R⇢ inM as R0. From the global Markov property of MRF, given the node
Rn and Rm, nodes in R⇢/(n,m) are conditionally independent from R
0, since all paths in
M between R⇢/(n,m) and R0 are separated by Rn and Rm. Therefore the configurations of
global MAP on M also maximize the conditional probability P (H⇢/(n,m)|(Hn, Hm)). The
node potential function for the new supernode R(n,m) is:
⇥R(H(n,m)) = maxH⇢/(n,m)
 
P (H⇢/(n,m)|(Hn, Hm))
 
+ ⇥R(Hn) + ⇥R(Hm)
= maxH⇢/(n,m)
(
m 1X
i=n+1
⇥R(Hi) +
m 1X
i=n
 R(Hi, Hi + 1)
)
+ ⇥R(Hn) + ⇥R(Hm)
(2.19)
The edge potential function of (Rs, R(n,m)) and (Rt, R(n,m)):
 C(H(n,m), Ht) =  C(Hn, Ht) (2.20)
 C(H(n,m), Hs) =  C(Hm, Hs) (2.21)
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Note that cancer node t can be the same as s, as in the case of R(7,9) in Figure 7.
When applying Weaver on MCF-7 data, initially we have 1,764,136 nodes, which can be
reduced to 2,588. Finding the variable configuration for node set R⇢/(n,m) to maximize
P (H⇢/(n,m)|(Hn, Hm)) can be viewed as linear (deg(R⇢/(n,m)) = 2) hidden Markov model
decoding problem, which can be e ciently solved in polynomial time by the Viterbi algo-
rithm.
2.2.13 Simulation method
Here we describe our methods of data simulation for evaluating Weaver. Although Weaver is
designed for WGS data, for the purpose of e cient evaluation with INTER chromosomal SVs
under di↵erent parameter settings, we used regions from chromosome 21 and 22 (coordinates
based on hg19, chr21:16M-40M, chr22:22M-50M) to build a pseudo reference genome. For
simplicity, we used chrA and chrB to represent those two regions from chr21 and chr22,
respectively.
We randomly chose 10 European individuals from 1KGP phase 1 phased haplotypes by
retrieving their SNP configurations with chrA and chrB regions. We then built parental
alleles by editing original human reference. The wgsim (Li et al., 2009) read simulator
was used, with 0.01 sequencing error to generate paired-end reads with 100bp read length
and 500bp mean insert size. The number of reads in simulation was used to control the
sequencing coverage.
Indeed, many factors which contribute to the signal noise of NGS mapping are hard
to model, including mappability, GC bias and repetitive regions not included in reference
genome. Weaver consider all of these factors when running on real data.
The outline of simulation process is given in Algorithm 1.
We modeled di↵erent alleles with di↵erent types of SVs. The SVs on chrA2 and chrB2
are non-chromothripsis, such that only deletions and duplications are observed. Therefore,
chrA2 and chrB2 can be viewed as normal chromosomes with several somatic deletions and
duplications. The only di↵erence is that chrA2 and chrB2 may have whole chromosome
amplifications. ChrA1 and chrB1 model chromothripsis event, in which both chromosomes
were shattered into multiple (N and M) non-overlapping fragments and randomly joined
together simultaneously.
There are three factors we considered in simulation: sequencing coverage (20X, 30X, 40X,
50X, 60X), overall allele ratio (1:1; 2:1; 2:2; 3:1; 3:2; 4:1; 4:2), and ten di↵erent individual.
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Algorithm 1 Simulating cancer genome sequencing data, with sequencing coverage X ,
allele ratio P : Q, individual M
Add N0SV (deletions or duplications) onto chrA and chrB, as germline homozygous dele-
tions/duplications.
Convert chosen individual haplotypeM from 1KGP into chrA and chrB, leading to chrA1,
chrA2, chrB1,chrB2
Simulate reads from chrA1, chrA2, chrB1,chrB2, as normal sample.
Add N1SV onto chrA1 and chrB1 as pre-aneuploid SVs.
Add N2SV onto chrA2 and chrB2 as pre-aneuploid SVs.
Randomly choose NA (NB) non-overlapping fragments
{chrA11,...,chrAN1 }({chrB11 ,...,chrBM1 }) from chrA1(chrB1).
Randomly shu✏e the set
 
chrA11, ..., chrA
N
1
 [  chrB11 , ..., chrBN1  
Link the shu✏ed fragments, leading to chrA1B1 which is a derived chromosome with
chromothripsis.
while CN of chrA1B1 < P do
Amplify (duplicate) chrA1B1.
add post-aneuploid SVs on one of the amplified chromosomes.
end while
while CN of chrA2 and chrB2 < Q do
Amplify chrA2 and chrB2.
add post-aneuploid SVs on one of the amplified chromosomes.
end while
Assume the overall length of all chromosome sequences simulated is L(bp), XL/200 pairs
of 100bp reads will be generated.
In total, 350 simulation datasets were generated.
In order to evaluate Weaver’s performance on entire chromosomal regions including cen-
tromeres and low complexity regions, we also designed a simulation dataset that derived
from entire chr17, chr19 and chr4. Chr17 and chr19 are two most rearranged chromosomes
according to our pan-cancer SV analysis on 600 TGCA deep WGS data (Figure 41), intra-
and inter-chromosomal SVs were modeled on chr17 and chr19, following the same method
described in Algorithm 1. On the other hand, chr4 is the most stable chromosome in terms
of SV density (Figure 41) and we only added small scale SVs on chr4. Therefore, we
selected chr17, chr19 and chr4 to evaluate Weaver on both highly rearranged and stable
chromosomal regions. We set the allele ratio in this simulation dataset as 2:1, which is
most frequent allele ratio in aneuploid cancer genome (Figure 45). Overall, 52 SVs (40 on
chr17 and chr19; 12 on chr4) were randomly simulated with the SV breakpoint density per
mega-base (0.314) approximating to the SV breakpoint density (0.327) of chromothripsis
chromosomes in CHROMOTHRIPSIS tumor subtype identified in Chapter 4. Specifi-
cally, deletions and duplications were simulated to have the median sizes approximating
to the median sizes (111,404bp for deletion and 142,922bp for duplication) identified in
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the pan-cancer study in Chapter 4. The number of deletion (9), duplication (11), intra-
(18) and inter-chromosomal SVs (14) were also chosen to be similar with observation from
Chapter 4.
2.3 Results
2.3.1 Application on simulated datasets
We first evaluated the performance of Weaver on simulated datasets on the following aspects.
Comparison with other SV finding tools
For SV breakpoint identification, we compared Weaver with CREST (v1.0) (Wang et al.,
2011), BreakDancer (v1.4.4) (Chen et al., 2009), and Delly (v0.0.11) (Rausch et al., 2012b).
CREST has achieved high specificity, but significantly lower sensitivity comparing with all
other tools. Both BreakDancer and Delly have consistently lower SN and SP comparing with
Weaver, on almost all test datasets. The detailed comparison is summarized in Table 1.
Although Weaver is designed for investigating somatic SVs, we selected two HapMap
genomes (NA18507 and NA12878) which has high coverage Illumina sequencing data avail-
able to test the power of Weaver as a generic SV detection tool. Since short range SVs
have marginal impact on CN, we focus our analysis on germline deletions and duplications
with range >2kb. Database of Genomic Variants (DGV10) (MacDonald et al., 2014) and
the variants reported in 1KGP (Mills et al., 2011) are used as gold standard of germline
SVs. 1184 of 1204 (98.3%) deletions and duplications reported by Weaver are annotated,
while Yang et al. (2013a) reported 931 in 969 (96.1%).
Comparison with other ASCNG methods
All SCNA detection methods based on high-throughput technologies including array com-
parative genomic hybridization (aCGH), SNP arrays and NGS adopt a similar workflow for
detection of SCNAs and the segmentation is the core part. Signals are used in segmentation,
including the signal intensity in array or read counts in NGS, and the b-allele frequency
in array or allele frequency in NGS. We first compare Weaver with CNVnator (Abyzov
et al., 2011) and HMMcopy (Ha et al., 2012), which are both designed for partitioning nor-
mal genome sequenced by NGS, ignoring allele information. The output of both tools is
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segmented genome regions with gain, loss or neutral labels, without exact copy numbers.
The segmentation results from all three tools are compared to simulation gold standard
with both SN and SP calculated. When SV information is omitted (SV ratio = 0), Weaver
achieved an average of 80.6% sensitivity and 92.5% specificity in finding copy number change
points (Figure 13), with increasing SV information, the performance of Weaver gradually
improved, showing that the advancement of considering copy number problem together
with SV. Even with false SV predictions (SV ratio > 1), Weaver still had accurate results.
CNVnator is consistently better than HMMcopy for both SN and SP.
To evaluate the performance on identifying exact ASCNG, we compared Weaver with
ASCAT (Van Loo et al., 2010) and CNVnator (Abyzov et al., 2011)+ThetA (Oesper et al.,
2013) (ThetA needs third party tool to perform segmentation). Since ASCAT was designed
for SNP array data, we converted our sequencing data to logR and BAF values for SNP
positions from Illumina HumanOmni2.5 BeadChip (2,015,318 SNP positions genome wide).
Overall 43,758 SNPs are within the simulated region. CNVnator+ThetA works on NGS
data, but only reports overall copy number. The consistency of Weaver with simulation gold
standard was 97.2%, while both ASCAT and CNVnator+ThetA had much lower consistency
(<20%).
The simulation results suggest that it is important to simultaneously consider SCNAs
and SVs, especially in highly rearranged cancer genomes.
Comparison with other SNP phasing tools
BEAGLE (Browning and Browning, 2009) is a statistical phasing method based on a popu-
lation reference-panel of phased chromosomes. We evaluated Weaver using switching error
rate, which is the standard metric for phasing accuracy (Browning and Browning, 2011).
The switching error is the proportion of switches in the inferred haplotypes to recover the
correct phase in an individual. In our evaluation, we left the phasing information of the
testing individual out, and used the rest 1KGP individuals as reference-panel. Overall,
Weaver reported an average switching error rate 0.2%, while BEAGLE had an error rate
of 3% on regions with imbalanced allele ratio. We have also observed a clear decrease of
switching rate for Weaver on dataset with increasing allele imbalance (Figure 5). We also
attempted to compare with a recently published method HARSH (Yang et al., 2013b). But
HARSH did not finish even on one simulated dataset after more than two weeks, making
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the comparison impossible to perform.
ASCNS accuracy
Overall Weaver achieved 97.1% accuracy in SV copy number inference and 95.7% accuracy
in SV phasing. The timing of SV can be inferred with pre- and post-aneuploid SVs. We
have correctly detected 97.3% pre- and 98.7% post-aneuploid SVs. SN and SP of reporting
SV with specific CNs are summarized in Figure 5(A)(B). The dispersion parameter  
is approximated by adding various degrees of random noises on original coverage from
simulation data. With increasing noise level (larger dispersion  ), both SN and SP drop.
However, based on our observation on the real datasets (as the example of MCF-7 dataset
in Figure 9), the dispersion is typically a bit greater than 1, suggesting that Weaver should
perform well on real cancer genome data.
Simulation with whole chromosomes
We also tested Weaver on simulation dataset derived from whole chr4, chr17 and chr19.
Overall, all 52 simulated SVs have been identified by Weaver, with 49 of exact base-pair
resolution breakpoint boundaries. The remaining 3 SVs have their breakpoints within low
complexity regions and the ‘soft-clip’ strategy (details in Section 2.2.2) failed to identify the
detailed breakpoints, however, ‘discordant paired-end’ strategy (details in Section 2.2.2) still
identified these 3 SVs with a rough estimation of their breakpoint locations. 100% ASCNS
reported by Weaver are consistent with simulation gold-standard.
In terms of relative timing comparing with aneuploidy, all 36 pre-aneuploid SVs in
this randomly generated dataset have been correctly identified. Weaver labeled 10 SVs
as post-aneuploid and 2 of them are incorrect since they were assigned to wrong alleles.
These 2 false positive post-aneuploid SVs are actually on the alleles which have not been
amplified, therefore no timing information shall be inferred on them. On ASCNG level, out
of 330,988,351bp regions simulated, 2,829,832bp regions (0.85%) have incorrect ASCNG. On
the level of overall copy number, ignoring allele information, 1,257,919bp regions (0.38%)
have incorrect copy number.
We have included this dataset as example in Weaver package for users to test.
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2.3.2 Application to TCGA ovarian cancer samples
Previous studies have shown that ovarian cancers (OVs) are featured with genetic instability,
including recurrent nonrandom chromosomal abnormalities, multiple chromosomal losses
and gains, and the presence of marker chromosomes (Diebold et al., 2000; Pejovic et al.,
2006; Micci et al., 2009; Wang et al., 2014). TCGA provided a detailed catalogue of genomic
aberrations in OV (Cancer Genome Atlas Research Network et al., 2011), suggesting that
the degree of SCNAs in OV is strikingly high comparing with other tumors. We have applied
Weaver on 45 high coverage (>15X on haplotype level) TCGA OV samples.
Genome-wide representation of Weaver result on one sample, TCGA-36-1571, is in Fig-
ure 14. There are two groups of highly inter-connected chromosomes: chr4-chr22 (Fig-
ure 15(A)) and chr6-chr14 (Figure 15(B)). By calculating the detailed copy number of
involved SVs and genomic regions, the chr4-chr22 group showed signatures of chromothrip-
sis of multiple chromosomes, while chr6-chr14 group showed extensive focal copy number
gains and is most likely to be formed by progressive process other than a single catastrophic
chromosome shattering event. Indeed, chr6-chr14 region has high number of FBIs, which are
fundamental to progressive rearrangements driven by BFB repair (Campbell et al., 2010;
Bignell et al., 2007; Li et al., 2014). Interestingly, FOXG1 gene is proximal to the BFB
FBI site on chr14 and highly amplified (Figure 15(B)). It was reported that the over-
expression of FOXG1 contributes to TGF-  resistance in OV, leading to loss of growth
inhibitory response to TGF- , which is a common feature of epithelial cancers (Chan et al.,
2009).
Figure 16(A) shows the overall copy number profile of OV chr19. Gene CCNE1 is
within the most significantly amplified region. Amplification of CCNE1 , which encodes
cyclin E1, is associated with primary treatment failure in women with OV. CCNE1 copy
number is validated as a dominant marker of patient outcome in OV (Etemadmoghadam
et al., 2009). Previous study (Cancer Genome Atlas Research Network et al., 2011) reported
that CCNE1 amplification is one of the most common focal copy number change events in
OV, occurring at a frequency of 20%.
One small region on 19p13.3 (4.6M-6.7M) is enriched with FBIs that lead to amplification
of 19p13.2. Especially TCGA-04-1514, TCGA-24-1552, TCGA-13-1491 and TCGA-13-0727
(4 out of 45 deep sequencing OV samples analyzed) have FBIs with breakpoints within
a < 60kbp region, as shown in Figure 16(B). Interestingly, the breakpoints are right
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around KDM4B from KDM4 protein family which are demethylases that target histone H3
on lysines 9 and 36 and histone H1.4 on lysine 26 (Berry and Janknecht, 2013). Various
studies have shown that KDM proteins, including KDM4B, are over-expressed in di↵erent
types of tumors and are required for e cient cancer cell growth.
Comparing to other chromosomes, chromosome 19 is significantly enriched with FBIs
(Figure 17). FBI, together with copy number profiles, is reliable indicator of BFBs (Zakov
et al., 2013), which serves as another potential application of Weaver which analyze SV
together with genomic copy number (details described in Chapter 4).
2.4 Discussion
Genomes of somatic cells undergo dramatic and complex genetic changes during cancer
development, including point mutations, SVs, large-scale gain or loss, and even aneuploidy.
Genome aneuploidy is a common feature of cancer cells. Recent pan-cancer analysis based on
WGS data estimated that over one third of the tumors have whole-genome duplication, and
the proportion can reach over 60% in some type of cancer (Zack et al., 2013). In addition,
genome aberrations caused by SVs and copy number changes are a common feature of a
wide variety of neoplastic lesions. Recent advances in NGS technologies have provided us
with an unprecedented opportunity to better characterize these di↵erent genomic changes
in cancer. However, even though methods have been separately developed to identify SVs
and SCNAs using NGS reads (Chen et al., 2009; Wang et al., 2011; Rausch et al., 2012b;
Hormozdiari et al., 2009; Yang et al., 2013a; Medvedev et al., 2010; Sindi et al., 2012),
no algorithm is currently available to simultaneously study SVs and SCNAs in aneuploid
cancer genomes. Therefore, Weaver represents the first method that quantifies allele-specific
copy numbers of SVs in cancer genomes and provides a more integrative solution to study
complex cancer genomic alterations.
We expect that Weaver will be very useful to refine the analysis of the existing datasets in
large-scale projects such as TCGA and ICGC, which were mostly sequenced using short read
NGS technology. The algorithm in Weaver is not restricted to short reads and can adapt to
data from longer read sequencing technology. However, it will remain di cult to completely
elucidate those very large complex SVs in cancer genomes, especially when the breakpoint
regions caused by SVs contain highly repetitive sequences. Single molecule systems for
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whole genome analysis such as Optical Mapping (Teague et al., 2010; Ray et al., 2013) will
provide unique solutions to study long-range large-scale SVs. An important direction could
be to integrate physical maps with NGS data to o↵er scalable and comprehensive view of
complex cancer genomes.
There are a number of areas that the Weaver algorithm can be further improved. Copy
number neutral events such as balanced inversions are not currently handled in Weaver.
Although Weaver sets no limit on maximum copy number, its accuracy in quantification
SVs is naturally hampered in highly repetitive regions, either in the reference genome or
in the cancer genome. In the case of MCF-7 genome (analyzed in Chapter 3), chromo-
some 3, 17 and 20 have regions with higher than 100X copies, and the estimation on copy
number and phasing of SVs within those regions may be less reliable. In addition, even
though the probabilistic graphical model employed in Weaver is generic to consider complex
tumor subclones caused by intratumor heterogeneity, current version of Weaver only works
for samples with a dominating tumor cell population (which can be estimated by tools such
as ABSOLUTE) with possible normal cell contamination. However, recently a number of
new algorithms have been developed to specifically identify subclonal structure of tumor
cell populations (Oesper et al., 2013; Miller et al., 2014; Prandi et al., 2014; Fischer et al.,
2014; Oesper et al., 2014; Deshwar et al., 2015; Malhotra et al., 2015; Beerenwinkel et al.,
2015; Popic et al., 2015). Very recently, TITAN (Ha et al., 2014) was developed to estimate
ASCNG in the a mixture of tumor cell population, though TITAN does not handle complex
SVs. Nevertheless, the results from these algorithms that identify tumor subclone architec-
ture are complementary to what Weaver can achieve. However, new methods are needed to
quantify ASCNS and understand how complex SVs interact in the context of a mixture of
aneuploid tumor cell population.
2.5 Figures and Tables
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MRFMappability GC Content
Purity ASCNG ASCNS Timing of SV Phasing
SV list
1KGP haplotypes
SNP list
Cancer Genome Graph SNP linkage SNP LD
BAM file
Figure 4: The method overview of Weaver. Red boxes represent input and green boxes
represent output. Yellow boxes show intermediate results. Dark green boxes show the
primary goals of Weaver that are novel and have never been tackled by other methods,
while light green ones show ‘by-products’ of Weaver that have also been demonstrated to
perform better in Weaver as compared to existing methods for these outputs.
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Figure 5: Performance of Weaver. In (A) and (B), SN and SP based on results from
Weaver are calculated for each ASCNS under di↵erent sequencing coverage dispersions (✓)
using simulation. Random fluctuations are imposed onto initial simulation dataset to create
testing dataset with specific dispersion. Both SN and SP decrease with increasing SV copy
number and dispersion. From observation on real cancer sequencing data, real dispersion
is slightly higher than one. (C) SN/SP is summarized for each ASCNG from Weaver. (D)
Switch error rate of Weaver and BEAGLE on simulated datasets with di↵erent allele ratios.
With imbalanced dataset, error rate of Weaver decreases to less than 0.5%.
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Figure 6: An example shows the outcome of Weaver, including the comparison with the AS-
CNG result from ASCAT (Van Loo et al., 2010) and ABSOLUTE (Carter et al., 2012). The
data used here is from an OV sample (TCGA-36-1571, details discussed in Section 2.3.2)
with WGS data for Weaver and array data for ASCAT and ABSOLUTE. ASCNG from
Weaver, ASCAT and ABSOLUTE are plotted as blue and green segments, indicating the
copy number of two di↵erent alleles as well as SVs involved. For region chr2:65958765-
73211197, ABSOLUTE has assigned ASCNG 3:2, while Weaver and ASCAT reported it as
2:2, which is more consistent with the allele frequency 0.5. Similarly, ASCAT has assigned
the region chr2:75056092-83513442 with ASCNG 3:2, while Weaver and ABSOLUTE re-
ported it as 2:2, which is more consistent with the allele frequency 0.5. Weaver reported
that region chr2:73211197-73504448 is a duplication that has two copies and linked (with
base-pair resolution SV breakpoints) to chr12. ABSOLUTE, however, has given the in-
correct boundaries (chr2:73073430-73355048) of the small duplication, while ASCAT has
assigned less accurate boundaries (chr2:73232809-73509065) and wrong copy numbers (5:2
is not consistent with the observed allele frequency). Both ASCAT and ABSOLUTE cannot
recognize how the duplicated copies are connected in the cancer genome.
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Figure 7: MRF model details. (A) Hypothetical cancer chromosomes with rearrangement
structure hidden. Orange and blue segments represent paternal/maternal allele. Red dashed
line represent linkages by SVs. (B) The Cancer Genome Graph, constructed from (A), with
nodes (boxes) representing genomic regions and edges representing reference (solid lines) or
cancer (dashed lines) adjacencies. (C) MRF representation in Weaver. Red boxes represent
cancer nodes(Rc) that have included SVs information; green boxes are the same with (B)
and representing genome nodes(R); the lines between genome nodes are genome edges(Er);
the lines between cancer nodes and genome nodes are cancer edges(Ec). More details of
cancer nodes are shown in Figure 8. (D) Blue boxes represent supernodes by clustering
blue shaded chains of genome nodes as shown in (C). (E) Input and output of MRF are
separated into genomic regions and SVs. For region R1, the input is observed coverage 30
and allele frequency 0.33; the output is 2 copies on allele 1 and 1 copy on allele 2. n is
a post-aneuploid deletion with 1 copy and both breakpoints are on allele 1 of chrA. t is a
pre-aneuploid deletion with 2 copies and both breakpoints are on allele 1 of chrB. SV m, p,
q and s are from the allele that has not been duplicated.
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Figure 8: Example of cancer node in MRF model. (A) shows the deletion n in Figure 7(A);
(B) shows in the details of cancer node Rn in Figure 7(C). The cancer node Rn is a
supernode composed by five variables, storing copy number of four linked genome nodes
(R6, R7, R9, R10) and the cancer node Rn itself, with allele and genotype information
omitted here for simplicity. The cancer node potential function provides the constraints on
all variables within the supernode (red). The cancer edge potential function imposes that
the corresponding variable from the supernode shall equals to the linked genome node. For
example, R06 has high potential to be equaling to R6 (shown in blue). genome edge potential
functions are illustrated in black.
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Figure 9: Posterior distribution of b and   given MCF-7 data. Dark red region represents
the most probable configuration of (b, ), which is measured as (19.4, 1.5).
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Figure 10: Two TCGA samples (OV.TCGA-36-1571, BRCA.TCGA-B6-A0RT) show if
samples are applicable to Weaver. Plots (A) and (C) show the clustering of MAF (Minor
Allele Frequency) and coverage on genomic segments. In plots (B) and (D), X axis is
the normal haplotype coverage and Y axis is the tumor haplotype coverage. In sample
OV.TCGA-36-1571, there are multiple MAF/Coverage clusters according to (A), which
implies the existence of SCNA, and from (B), the inferred normal haplotype coverage is 2.0
and tumor haplotype coverage is 19.8. However for sample BRCA.TCGA-B6-A0RT, only
one MAF/Coverage cluster has been observed, implying no SCNA. Moreover from (D), no
optimal tumor/normal coverage pair exists.
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Figure 11: Testing on simulated data with over-dispersion   = 1.5, Weaver achieved
R2 = 0.998 when inferring µ0, showing that Weaver has high accuracy when inferring
primary tumor purity.
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Figure 12: Weak correlation (Pearson’s correlation coe cient = 0.258) between the number
of supporting discordant read pairs and ASCNS in TCGA-36-1571 and Weaver model does
not consider discordant read pairs in ASCNS inference.
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Figure 13: SN and SP in finding SCNA breakpoints were plotted for Weaver, CNVnator
and HMMcopy. X axis represents the ratio of correct SVs provided to Weaver and 0 stands
for the case in which no SV was provided. Both SN and SP for CNVnator and HMMcopy are
stable since none of current tools designed for copy number analysis, including CNVnator
and HMMcopy, utilize SV information. Larger than 1 ratio means that false positive SVs
have been added to Weaver input to estimate its performance when false positive SVs have
been detected.
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Figure 14: Circos (Krzywinski et al., 2009) overview of the genomic landscape of a TCGA
OV sample (TCGA-36-1571). INTER chromosomal and INTRA chromosomal SVs with size
larger than 10Mbp are illustrated as red (one copy) and purple (>one copy) lines. Short
range deletions, duplications and inversions (imbalanced) are presented as blue, red, and
green vertical bars, respectively. ASCNGs are plotted as blue and green segments. There are
two groups of highly inter-connected chromosomes: chr4-chr22 (details in Figure 15(A))
and chr6-chr14 (details in Figure 15(B)).
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Figure 15: Chromothripsis and BFB observed in one TCGA OV sample. (A) ASCNG is
plotted by blue and green segments. Most of SVs linking chr4 and chr22 have copy number
one (red lines). (B) Instead of ASCNG, overall copy number profile is plotted with green
segments with maximum copy number 62. Three high-coverage FBIs (red fold-back arrows)
are observed at boundaries of highly amplified region of chr14, indicating that many rounds
of BFB cycles happened. Gene FOXG1 is within the FBI boundary and has been highly
amplified through BFB.
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Figure 16: Copy number landscape of chromosome 19 altered by recurrent SVs. (A) The
overall copy number profile across 45 OV samples on chr11. The Chromosome bands are
highlighted with red and blue, representing the frequently amplified and deleted regions
from GISTIC analysis of TCGA OV array data (Cancer Genome Atlas Research Network
et al., 2011). CCNE1 gene is within most significantly amplified region. Four pink tracks
represent regions on which gross copy number profile has changed and all four regions have
recurrent FBIs. (B) Four OV samples with recurrent FBI at KDM4B are illustrated. Red
fold-back arrows represent FBIs while blue lines represent other INTRA chromosomal SVs.
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Figure 17: Number of FBIs on every 10Mbp OV genome are calculated across 45 OV
genomes. Chromosome 19 is significantly enriched with FBI, indicating that the amplifica-
tion of chromosome 19 is specifically driven by FBIs (details in Figure 16).
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Chapter 3
Analysis of complex SVs in
MCF-7 and HeLa Genomes
3.1 Introduction
MCF-7 is one of the most widely used cell line models for estrogen-positive breast carci-
noma (Lee et al., 2015), derived from a pleural e↵usion taken from a patient with metastatic
breast carcinoma (Soule et al., 1973). Aneuploidy is a core feature of MCF-7 genome and
has been previously reported by spectral karyotyping (Kyto¨la¨ et al., 2000; Rummukainen
et al., 2001; Rondo´n-Lagos et al., 2014), comparative genomic hybridization (CGH) (Kyto¨la¨
et al., 2000; Rummukainen et al., 2001) and array CGH (Neve et al., 2006; Jo¨nsson et al.,
2007). Figure 1 shows the multi-color FISH karyotype of the aneuploid MCF-7 genome,
for example, six copies of chromosome 14 are present in MCF-7, instead of two. More
recently, low coverage BAC sequencing has generated a raw map of MCF-7 genome rear-
rangements (Hampton et al., 2009). However, no comprehensive WGS analysis has been
performed for MCF-7 cell line. To understand how SVs further remodel the transcriptional
and epigenetic behavior of MCF-7, an integrated analysis based on MCF-7 specific genome
information is needed. We utilize the Weaver algorithm to perform detailed analysis that
integrates functional genomic data of MCF-7 to investigate: i) the relationship between
allele specific copy number of genome (ASCNG) and allelic expression of genes, finding out
genes with allele specific expression after ASCNG normalization; ii) the relationship between
chromatin interactions and SVs, elucidating how SVs lead to cancer specific chromatin in-
teractions as well as its transcriptional impact.
Established in 1951 from cervical cancer cells, the HeLa cell line was the first human-
derived cells successfully immortalized in vitro and has been mentioned in more than 74,000
PubMed abstracts (approximately 0.3%) (Adey et al., 2013), demonstrating the omnipres-
ence of HeLa cell line in modern biomedical research. Despite the importance of HeLa cell
line, the detailed genomic architecture of HeLa remains largely unexplored beyond its kary-
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otype (Macville et al., 1999a), until two recent sequencing studies for HeLa CCL-2 (Adey
et al., 2013) and Kyoto (Landry et al., 2013) strains. Both studies treated HeLa SV and
SCNA profiles independently in their analysis and we will reuse the same WGS data gen-
erated for CCL-2 strain (data from Kyoto strain is not available) and perform Weaver
integrative analysis to provide base-pair resolution of ASCNG and ASCNS, and investigate
complex SVs for the HeLa genome.
3.2 Methods
3.2.1 Data preparation
For MCF-7, we generated high coverage (⇠ 100X) 100bp paired-end WGS data. Reads were
aligned onto human reference genome (hg19) by BWA (Li and Durbin, 2009) mem method
with default parameters, followed by duplicate removal, quality score recalibration and
local INDEL realignment using GATK (McKenna et al., 2010). MCF-7 Optical Mapping
(OM) (Schwartz et al., 1993) data was generated by David C. Schwartz lab in University of
Wisconsin-Madison. WGS data for HeLa CCL-2 cell line with 88X was obtained from Adey
et al. (2013). Transcriptome and ChIA-PET interactions data used in this study were
downloaded from ENCODE UCSC browser (Rosenbloom et al., 2010).
3.2.2 Optical mapping as independent validation of complex
long-range SVs
The OM constructs ordered restriction maps (Rmaps) spanning large region of genome
(300-2,500 kb), which provides long range linkage information that current NGS technology
is short of (Schwartz et al., 1993; Gupta et al., 2015). The detailed workflow of OM is
illustrated in Figure 18(A). OM has been applied to characterize the full range of SVs
in normal human populations (Teague et al., 2010). A recent analysis on a primary multi-
ple myeloma genome by combing OM technology and NGS, comprehensively characterized
widespread genomic variations across the entire length spectrum of variation (Gupta et al.,
2015). Examples of deletion, insertion and inversion detection by OM are shown in Fig-
ure 18(B).
MCF-7 genome OM Rmaps were first aligned on to reference genome by a tool called
Software for Optical Mapping Analysis (SOMA) (Valouev et al., 2006), which applies a
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modified Needleman-Wunsch dynamic programming algorithm to find an optimal global
alignment between two restriction maps, with at least 5 aligned chunks and minimum align-
ment score 8 (parameters used in Teague et al. (2010)). Using the same parameter setting of
SOMA, all initially unaligned ‘Rmaps’ were aligned to cancer reference, built by long-range
SVs detected by NGS, to serve as independent validation of those long-range SVs in MCF-7
genome.
3.3 Results
3.3.1 Weaver analysis of MCF-7 genome
We applied Weaver to the whole-genome DNA sequencing data of the MCF-7 breast cancer
cell line, with approximately 100X overall coverage and 20X haplotype level coverage (esti-
mated by Weaver). Genome-wide ASCNS and ASCNG are shown in Figure 19. Figure 20
shows ASCNG on all chromosomes. The ASCNG profile is largely consistent with previous
karyotyping result in Figure 1. 68.3% of MCF-7 genome have imbalanced ASCNG, en-
abling accurate phasing of SNPs and distal SVs. Weaver identified 546 SVs with 83.3% have
copy number greater than 1. Moreover Weaver found 276 post-aneuploid SVs, especially two
deletions, Del1 (chr9:21,837,011-22,081,282) and Del2 (chr9:21,819,514-21,989,631), within
theMTAP-CDKN2A/B region (Figure 22), where deletions have been frequently observed
in various cancers (Zack et al., 2013; Brennan et al., 2013). Weaver found that the short
arm of chr9 is triplicated with LOH, having mutually exclusive Del1 and Del2, with copy
number 2 and 1, respectively. The copy number of deletions implies the region has been
amplified twice. Before the first amplification, which changed copy number from one to
two, no deletion occurred. After the first amplification and before the second amplifica-
tion, Del1 emerged on one chromosome, which was then duplicated in the second round of
amplification, leading to two copies of Del1. Independent from Del1, Del2 was formed in
approximately the same region of the other chromosome after the first amplification. Such
evolutionary information cannot be revealed without SV copy number quantification.
The ASCNG generated by Weaver in MCF-7 demonstrated that detailed cancer genome
analysis has the potential application in helping better interpret cancer functional genomic
sequencing data. The recent work in HeLa cells has also suggested the need of allele-specific
analysis of transcriptome and epigenome data (Adey et al., 2013). Figure 21 shows that
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ASCNG predicted by Weaver correlates well with the allele-specific expression in MCF-7.
We have also analyzed the allelic behavior of other epigenetic data generated by ENCODE on
MCF-7, including PolII and CTCF binding, DNase and H3k4me3 modification (Table 3).
3.3.2 OM supports the MCF-7 SVs identified by Weaver
We selected 268 long range MCF-7 SVs detected by Weaver and built in silico ‘Cancer Ref-
erence Map’ from these SVs by taking together 300kbp flanking regions of two breakpoints
for each SV. We used SOMA to align all initially unaligned OM Rmaps onto 238 in silico
‘Cancer Reference Map’. It turned out that 235 of them have OM supports. The potential
reason for SVs missed by OM is that the OM Rmap coverage on the cancer allele rearranged
from SV might be low or even zero, leading to insu cient OM alignment quality.
An example of OM supporting TD detected by NGS, is shown in Figure 28. Two
OM Rmaps are shown as blue lines, with red dots represent theoretical cutting cites of
restriction enzymes on reference genome and purple dots represent cutting sites that missed
by OM. Black number on each segment of OM Rmaps shows the expected length (kb) of
OM Rmaps between two cutting sites on reference and blue number under each segment
shows the observed length (kb) of OM Rmaps from OM device. The mapping qualify of
OM Rmaps produced by SOMA is essentially measuring the similarity between expected
and observed OM Rmap length. The most important di↵erence when dealing with OM
data on rearranged cancer genome and normal genome is that long-range SVs in cancer
genome may edit the expected length of OM Rmaps covering the breakpoints of SVs. As in
Figure 28, the expected length of OM Rmap covering the TD breakpoint is 23.7kb, while
the observed lengths of two OM Rmaps are 22.4kb and 23.1kb, respectively. The strong
accordance between expected and observed OM Rmap length on multiple OM Rmaps may
serve as an independent validation of this TD initially detected by NGS. Figure 29 shows
another example of validating FBIs by OM.
Applying OM on MCF-7 data, we observed that SVs are not necessarily on the amplified
allele. In Figure 26, TD that leads to RPS6KB1-VMP1 fusion is not on highly amplified
chr17 segments. Both dark (45 copies) and light blue (10 copies) segments stand for MCF-7
chromosomes originated from the same parental allele, while green (four copies) segment
stands for chromosome originated from the other parental allele. Dark blue chromosomes are
formed by a series of large scale SVs, including the deletion shown in this Figure, and have
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been amplified into extreme copies. Red dots represent BamHI enzyme cutting sites detected
by OM, and purple ones are missed cutting sites by OM. Red numbers are OM readout for
DNA fragments cut by BamHI; black numbers are expected DNA fragment size on reference
genome. The fragment omdb:170127721:2049881 0 303 (alignment score 11.62) shows that
the TD and deletion, although sharing close coordinates on reference genome (less than
10kb), are physically on separate chromosomes, indicating that they followed independent
formation paths during tumorigenesis. This example shows the inherent limitation of short
NGS reads in phasing. In this case, it is not possible to figure out the phasing configuration
of the TD and deletion, since they originate from the same parental allele.
3.3.3 ChIA-PET and SVs in cancer genome
Chromatin interaction analysis with paired-end tag sequencing (ChIA-PET) is a technology
that combines 3C-based methods to ChIP, by probing chromosomal contacts that involve
certain protein factors (Fullwood et al., 2009). The procedures of ChIA-PET are shown
in Figure 23. ChIA-PET has been applied to identify transcriptional enhancers and their
target genes (Li et al., 2012) since transcription involves PolII.
The expected range of chromatin interactions probed by ChIA-PET is  400kbp, how-
ever, ‘unexpected’ interactions with ultra-long range were also observed in previous anal-
ysis (Li et al., 2012). We hypothesize that some of those ‘unexpected’ ultra-long range
interactions were established by long range SVs in cancer genome. We select ultra-long
range ChIA-PET clusters by following criteria: i) PET count > 4 for each PET cluster;
ii) INTRA chromosomal clusters with genomic span > 400kbp. We search MCF-7 SV list
against each ultra-long range ChIA-PET cluster and define a ChIA-PET cluster being corre-
lated with a SV if: i) the orientation of SV is consistent with the relative position of SV and
ChIA-PET cluster; ii) the new genomic span of ChIA-PET in MCF-7 genome remodeled by
detected SV is  400kbp, but still > 8K, to exclude ChIA-PET cluster from self-ligation on
the same DNA fragment (Li et al., 2012). Indeed, we find many potentially artificial ‘MCF-7
specific interactions’ since when considering SVs, they reside right on two SV breakpoints
and likely originate from single binding site on either side of SV, rather than two distinct
ones (details in Table 2). This finding indicates that cell type specific genome information
is indispensable when studying epigenetic data, especially for cancer genomes which typi-
cally have large scale SVs. For SV related INTRA chromosomal ChIA-PET clusters, the
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median genomic span on human reference and MCF-7 cancer genome is 3,353,180bp and
212,803bp, respectively. SV related INTER chromosomal ChIA-PET clusters are on the
same chromosome in MCF-7 cancer genome and the median genomic span is 151,872bp. To
test the significance of correlation between MCF-7 SV and MCF-7 long range ChIA-PET
clusters, we also searched the correlation between MCF-7 SV and ChIA-PET clusters from
other cell lines (Table 2), which is significantly weaker (Fisher’s exact test).
Additionally, we have also discovered that the phasing of di↵erent SVs by Weaver has
enabled the analysis of interaction between genomic rearrangements and long-range gene
regulation at much broader scale. In Figure 24, blue/green segments represent chromo-
somes originated from two di↵erent alleles. Two intrachromosomal SVs on chr11, both
amplified to three copies and one the same allele according to Weaver, are indicated by
blue lines, while the intact chr11 allele (green) has been amplified to two copies. The de-
rived region from two allele-specific INTRA chromosomal SVs brought gene SLC35C1 and
gene PRSS23, which are ⇠40Mbp apart and on di↵erent chromosome arms in the normal
genome, to only ⇠50kb on three copies of cancer derived chromosomes plotted as blue seg-
ments. ChIA-PET data reveals that, the physical proximity of SLC35C1 and PRSS23 in
cancer derived chr11 potentially leads to the MCF-7 specific promoter-promoter interaction
(highlighted in green) of these two genes. RNA-seq reads aligned on two SNV sites within
SCL35C1 exons show significantly greater (binomial test P-value < 1e 5) blue/green ra-
tio as compared to DNA copy ratio (3/2), indicating that blue allele-specific expression of
SLC35C1 has been elevated, which was likely caused by the chromatin interaction formed
by the allele-specific SVs. The MCF-7 cancer genome structure in Figure 24 revealed by
Weaver is also validated by OM (Figure 25).
We have also identified a potential chromothripsis event comprised of eight fragments
from chr17 and nine fragments from chr20 in MCF-7 genome, and can be supported by
long-range ChIA-PET cluster. In Figure 27, ChIA-PET cluster has linked two flanking
promoters (BMP7 and INTS2) together, proving the existence of the entire complex cancer
contig. Note that this region has been amplified many times and the chr20 amplified region
is also linking to another amplified region on chr20.
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3.3.4 Weaver analysis of HeLa CCL-2 genome
We applied Weaver to the WGS data of the HeLa cells CCL-2 generated by Adey et al.
(2013). Haplotype level coverage is approximately 28X. The original study by Adey et al.
(2013) reported 12 INTER chromosomal SVs, and no large scale INTRA chromosomal SV
was reported (only deletions and inversions with size < 10kb are reported). However, from
our analysis on the same data, we have identified 8 INTER chromosomal and 86 INTRA
chromosomal SVs (if INTRA chromosomal SVs are deletion or TD type, only those with
size > 20kb are reported). Overall, there are 62 genes harboring SV breakpoints.
Genome-wide representation of the Weaver results on HeLa is in Figure 30. Figure 31
shows that ASCNG predicted by Weaver correlates well with the allele-specific expression
in HeLa. The large-scale aneuploidy and LOH region is very consistent with Adey et al.
(2013). Comparing Weaver’s result with Adey et al. (2013), for all genomic regions with
copy number profiled, 96.1% have consistent overall copy number estimation between two
studies. For ASCNG, the consistency is 97.3% by comparing Weaver output with Table
S13 in Adey et al. (2013) (and also Figure 1a in Adey et al. (2013) for visual inspection
of the consistency). Those copy number inconsistent regions includes the deletion of FHIT
gene (Wistuba et al., 1997) (Figure 32), which is a tumor suppressor gene frequently to
have no expression in various human tumors including the HeLa cell line (Otterson et al.,
1998; Wistuba et al., 1997; Druck et al., 1997).
Chr11 and chr19 have undergone extensive amount of structural rearrangements (Fig-
ure 33 and Figure 34), which has also been reported by (Landry et al., 2013) in HeLa
Kyoto cell line. For chr11, Weaver results show that all SVs are on allele 1 (blue) and allele
2 (green) is intact and free from SVs. Both copy number one and two are found for chr11
SVs on allele 1 and SVs with ASCNS two emerged before allele 1 amplification and are
pre-aneuploid, while those SVs with ASCNS one happened after the amplification of allele
1 and are post-aneuploid. The SVs are likely to be formed by chromothripsis (Stephens
et al., 2011). For Weaver results on chr19, all SVs have copy number one and on one copy
of allele 1 (blue), excluding the INTER chromosomal SV (chr13:55878043-chr19:12898480)
which is on allele 2 (green). Since no FBI has been observed on chr19, the elevated rate
of rearrangement on chr19 is not from BFB cycles. Moreover, the high allele specificity of
SVs on allele 1 implies that allele 1 of chr19 is rearranged from an one-o↵ chromothripsis
event. Weaver has labeled all INTRA chromosomal SVs on chr19 as post-aneuploidy, such
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that one copy of allele 1 is left intact from SVs after the initial amplification of allele 1,
which is consistent with previous observation that there are two normal copies of chr19 in
HeLa (Macville et al., 1999b).
3.4 Discussion
We provide the first base-pair resolution ASCNS and ASCNG map for MCF-7 and HeLa.
We believe the rearrangement map will serve as high-quality reference genomes for past and
future experiments relying on these cell lines. With Weaver, we were able to assign di↵erent
timing for the two chromothripsis events on chr11 and chr19 of HeLa. The chromothripsis on
chr11 happened before aneuploidy (since most of the breakpoints have copy number > 1)
while chromothripsis on chr19 happened after aneuploidy (since most of the breakpoints
have copy number = 1).
NGS technology delivers the highest throughput and accuracy among all available se-
quencing technologies, including Sanger and ‘third generation sequencing’ provided by
PacBio. However NGS itself is not su cient in uncovering entire genome rearrangement
catalogue due to its short read length. Hybrid methods that combine the strengths of mul-
tiple sequencing technologies have been proposed (Koren et al., 2012) and applied by Adey
et al. (2013) in providing accurately phased HeLa genome. Of 15 cell lines in tier one and
two of ENCODE project (ENCODE Project Consortium et al., 2012), six (K562, A549,
HeLa-S3, HepG2, MCF-7 and SK-N-SH) are cancer cell lines, with elevated rate of genome
alterations expected. We believe the integrated SV and SCNA analysis enabled with Weaver,
together with hybrid sequencing e↵orts, will help shed light on the hidden structure of com-
plex rearrangements and further aid the functional interpretation of ENCODE data in the
context of cancer cell lines specific genomes instead of reference human genome.
3.5 Figures and Tables
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Figure 18: (A) Overview of OM technology. (a) Genomic DNA is extracted and (b)
immobilized on charged surfaces in elongated conformation using microfluidics. (c) DNA
molecular is restriction-digested, stained with a fluorescent dye (YOYO-1), and then imaged
using automated epifluorescence microscopy workstations. (d) Custom image processing
software is used to process image and generate single molecule ordered restriction maps
(Rmaps). (e) Millions of Rmaps are collected and then assembled using an iterative assembly
algorithm to identify SV across the genome (Ray et al., 2013). The figure was obtained
from Gupta et al. (2015). (B) Application of OM in finding SVs. The blue and orange
segments represent reference restriction map and OM Rmaps, respectively. In the case of
deletion, a chunk of reference restriction map is missed in Rmaps; in case of insertion (or
TD), a chunk of Rmaps are not presented in reference restriction map; in case of inversion, a
chunk of reference restriction map is reversely presented in Rmaps. The figure was obtained
from Teague et al. (2010).
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Figure 19: Overview of the genomic landscape of MCF-7 cell line. INTER chromosomal
and INTRA chromosomal SVs with size larger than 10Mbp are illustrated as red (one
copy) and purple (>one copy) lines. Short range deletions, duplications and inversions
(imbalanced) are presented as blue, red, and green vertical bars, respectively. Chr1, chr3,
chr17 and chr20 have inter-connected focal amplifications. ASCNGs are plotted as blue and
green segments.
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Figure 20: Detailed ASCNG profile of MCF-7 genome. Balanced ASCNG ratios (1:1, 2:2,
3:3) are plotted with blue color. Imbalanced and LOH ASCNG ratios are plotted in red and
green color, respectively. For example on chromosome X, one parental allele has entirely
lost during the MCF-7 tumorigenesis, leading to LOH. 63% of the remaining parental allele
has been amplified to two copies, 37% has been amplified to three copies.
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Figure 21: Boxplot showing the distribution of allelic expression ratio measured by RNA-
seq for di↵erent allele copy number categories. Red stars indicate allele copy ratio and serve
as expected allelic gene expression ratio under the hypothesis that expression of gene is
proportional to its copy number. The median allelic expression ratio matches well with the
expected value from copy number, showing that ASCNG measured by Weaver is accurate
and can explain the majority of allelic gene expression.
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Figure 22: (A) Dark blue segments (two copies) and light blue segment (one copy) repre-
sent MCF-7 chromosomes originated from the same allele. The other allele was lost during
tumorigenesis, leaving the region as LOH. (B) The predicted evolution of MCF-7 chro-
mosomes. (C) MTAP-CDKN2B AS1 fusion transcripts, formed by Del1 (two dark blue
chromosomes), can be detected by RNA-seq in MCF-7. Five alternative fusion splice junc-
tions (with supporting RNA-seq reads) linking from one exon on MTAP to five di↵erent
exons on CDKN2B AS1 are plotted as black lines between two gene models.
62
PolII
ChIA-PET
Fixation and shearing
Figure 23: Overview of ChIA-PET procedure. ChIA-PET can detect spatial genomic
contacts by crosslinking, DNA fragmentation, DNA fragment ligation and deep sequencing.
ChIA PET includes a ChIP step to enrich for complexes that contain a specific protein,
such as RNA polymerase II (Pol II) in this figure. The corporation in transcription between
red and green genes is detected by ChIA-PET. The figure was obtained from Shlyueva et al.
(2014).
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Figure 24: Allele-specific gene expression likely driven by SV. Blue/green segments rep-
resent chromosomes originated from two di↵erent alleles. Two intrachromosomal SVs on
chr11, both with three copies, are indicated by blue lines. Weaver assigned both SVs with
copy number as three and they are also on the same allele. The two SVs link SLC35C1
and PRSS23, which are ⇠40Mbp apart and on di↵erent chromosome arms in the normal
genome, to only ⇠50kb on three copies of cancer derived chromosomes plotted as blue seg-
ments. ChIA-PET data reveals that, the physical proximity of SLC35C1 and PRSS23 in
cancer derived chr11 potentially leads to the MCF-7 specific promoter-promoter interaction
(highlighted in green) of these two genes. RNA-seq reads aligned on two SNV sites within
SCL35C1 exons show significantly greater (binomial test P-value < 1e 5) blue/green ra-
tio as compared to DNA copy ratio (3/2), indicating that blue allele-specific expression of
SLC35C1 has been elevated, which was likely caused by the chromatin interaction formed
by the allele-specific SVs.
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Figure 25: OM as an independent validation of SV phasing in Figure 24. Four OM rMaps
have been found consistent with the phasing in chr11. Purple dots show the BamH1 cutting
sites missed by OM Rmaps. Black and blue numbers represent the size (kb) of BamH1
cutting fragments on reference genome and cancer SV; red and purple numbers represent
the size of OM fragments from normal cutting and missed cutting, respectively.
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Figure 26: TD that leads to RPS6KB1-VMP1 fusion is not on highly amplified chr17
segments. Both dark (45 copies) and light blue (10 copies) segments stand for MCF-7
chromosomes originated from the same parental allele, while green (four copies) segment
stands for chromosome originated from the other parental allele. Dark blue chromosomes are
formed by a series of large scale SVs, including the deletion shown in this Figure, and have
been amplified into extreme copies. Red dots represent BamHI enzyme cutting sites detected
by OM, and purple ones are missed cutting sites by OM. Red numbers are OM readout for
DNA fragments cut by BamHI; black numbers are expected DNA fragment size on reference
genome. The fragment omdb:170127721:2049881 0 303 (alignment score 11.62) shows that
the TD and deletion, although sharing close coordinates on reference genome (less than
10k), are physically on separate chromosomes, indicating that they followed independent
formation paths during tumorigenesis. This example shows the inherent limitation of short
NGS reads in phasing. In this case, it is not possible to figure out the phasing configuration
of the TD and deletion, since they originate from the same parental allele.
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Figure 27: Cancer contig comprised of eight fragments from chr17 and nine fragments from
chr20 in MCF-7 genome. ChIA-PET cluster has linked two flanking promoters (BMP7 and
INTS2) together, proving the existence of the entire complex cancer contig. Note that
this region has been amplified many times and the chr20 amplified region is also linking to
another amplified region on chr20.
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Figure 28: OM supports a TD in MCF-7 genome. The TD is pre-aneuploid that a whole
chromosome amplification happened after the initial TD.
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Figure 29: FBI been found by combining OM and NGS. (A) shows di↵erence between
‘balanced’ inversion, with two breakpoint junctions, and ‘imbalanced’ (fold-back) inversion,
with only one breakpoint junction. (B) shows a FBI on FOXP2 gene on MCF-7 chromosome
7. The FBI is also confirmed by OM.
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Figure 30: Overview of the genomic landscape of HeLa CCL-2, with legend the same as in
Figure 19. Chr11 and chr19 have undergone extensive amount of structural rearrangements
with di↵erent ASCNS. Chr11 is enriched with SVs with copy number higher than one (purple
lines); SVs in chr19 are primarily with copy number one (red lines).
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Figure 31: Boxplot showing the distribution of allelic expression ratio measured by RNA-
seq for di↵erent allele copy number categories in HeLa. Red stars indicate allele copy ratio
and serve as expected allelic gene expression ratio under the hypothesis that expression of
gene is proportional to its copy number. The median allelic expression ratio matches well
with the expected value from copy number, showing that ASCNG measured by Weaver
is accurate and can explain the majority of allelic gene expression. The most significant
outliers are in MYC gene locus, that the ASCNG ratio within MYC region is 3:1, however,
the allele specific expression ratio is much higher (337:17 on chr8:128,748,498). Adey et al.
(2013) has also observed this allele specific expression behavior of MYC and found that the
MYC copy elevated in expression is actually on the HPV-18-integrated allele, implying that
HPV integration might regulate expression of nearby genes on a allele specific manner.
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Figure 32: Complex SVs on fragile histidine triad (FHIT ) gene region in HeLa CCL-2
strain. Blue/green segments represent chromosomes originated from the same parental allele
in normal genome. Allele frequency is plotted by calculating the minor allele frequency of
germline SNPs. There are five SVs in this small region and all have copy number one. Adey
et al. (2013) does not report these SVs or SCNAs in FHIT gene.
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Figure 33: Rearrangements and ASCN of chromosome 11 in HeLa CCL-2. Rearrangements
are plotted by their orientation. D: deletion-type; TD: tandem duplication-type; HH: head-
to-head inverted; TT: tail-to-tail inverted. All SVs on chr11 are on allele 1 (blue). Both copy
number one and two are found for chr11 SVs. SVs with copy number two emerged before
allele 1 amplification; while those with copy number one happened after the amplification.
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Figure 34: Rearrangements and ASCN of chromosome 19 in HeLa CCL-2. All SVs on
chr19 has copy number one and on one copy of allele 1 (blue), excluding the INTER chro-
mosomal SV (chr13:55878043-chr19:12898480) which is on allele 2 (green). The high allele
specificity of SVs and the fact that there is no FBI been observed are implying allele 1 of
chr19 is rearranged from an one-o↵ chromothripsis event. Weaver has labeled all INTRA
chromosomal SVs on chr19 as post-aneuploidy, such that one copy of allele 1 is left in-
tact from SVs after the initial amplification of allele 1, which is consistent with previous
observation that there are two normal copies of chr19 in HeLa (Macville et al., 1999b) .
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Table 2: Correlation between MCF-7 SVs and ChIA-PET clusters of various cell lines
Dataset MCF-7 PolII Hela PolII K562 NB4 Hct116
+ CTCF+ERa PolII+CTCF
Long range overall 4,708 305 2,057 42 198
Correlate 485 2 6 0 0
P-value NA < 0.0001 < 0.0001 0.0296 < 0.0001
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Table 3: MCF-7 allele specific gene expression and epigenetic peaks. If a gene or peak
region contains at least one SNP (ASCNG on both alleles > 0) in MCF-7 genome, it is
categorized as allele informative. For each allele informative gene or peak, we test the allele
specific expression or binding from NGS reads against MCF-7 ASCNG profile by binomial
test. If the p-value is < 0.05, the gene or peak is categorized as allele specific. The gene or
peak is categorized as monoallele if its expression or binding has only been observed on one
allele from NGS data.
Dataset Overall Allele informative Allele specific Monoallele
Refseq genes 23,953 6,238 1,333 131
PolII Peaks 83,851 1,891 200 117
CTCF Peaks 44,354 3,804 317 89
Dase Peaks 118,429 2,966 344 242
H3k4me3 Peaks 140,964 5,272 635 245
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Chapter 4
Pan-cancer analysis of SVs in
TCGA WGS samples
4.1 Introduction
With more and more data generated for cancer genome, especially from the international
e↵orts in cancer genome sequencing including the TCGA project, ‘pan-cancer’ analysis that
focuses on genomic features across tumor types is a paradigm shift in recent cancer re-
search. Especially, di↵erent stratification methods have been proposed to analyze cancer
genome across tumor types and investigate properties shared independently from tissue
types. Ciriello et al. (2013) utilized a few hundred potentially functional oncogenic signa-
tures by reducing the complexity of thousands of molecular alterations, and stratified tumors
across tissues into subtypes featured with mutation or copy number alterations. Hoadley
et al. (2014) proposed a unified classification with 11 major subtypes for 3,527 samples
from 12 cancer types, revealing cases that tumors from di↵erent tissue-of-origins share more
similar molecular signatures than those from the same tissue.
The pan-cancer analysis is essential in personalized medicine and drug repositioning by
revealing molecular insights into diseases in individual patients, and enabling the segregation
of broad disease categories into smaller, target-centric subtypes, which might be shared
across tumor types. Originally developed for HER2-positive breast cancer (Vogel et al.,
2002), trastuzumab has now been used for the treatment of a new HER2-positive subtype
of gastric cancer, demonstrating the power of pan-cancer analysis (Rose and Bekaii-Saab,
2011; Li and Jones, 2012). Another example is imatinib (Gleevec and Glivec), a drug initially
developed to treat chronic myelogenous leukemia whose indications were expanded to other
cancers on the basis of shared underlying molecular pathways revealed by studies across
cancer types (Fishman and Porter, 2005; Boguski et al., 2009).
Despite providing much more comprehensive view of tumor genome than traditional
analysis, most of existing pan-cancer analysis are only focusing on mutations, gene expres-
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sions and SCNAs. However, the investigation into pan-cancer behavior of cancer genome
SVs is limited, partially due to the shortage of available tumor genome WGS data and the
computational resources/methods for precise interpretation. The Weaver algorithm, which
combines the analysis of SV together with SCNAs in a probabilistic graphical model, fits
well to the need of understanding pan-cancer feature of complex cancer genome SVs.
We screened TCGA WGS datasets, as listed in Table 4, there are 600 samples (as of
March 12, 2015) from 17 di↵erent cancer histological types in TCGA that have enough
coverage for comprehensive SV and copy number variation analysis (details in Section 4.2).
Currently there is no comprehensive analysis of these deep sequencing data published and
we will apply Weaver (method described in Chapter 2) framework to deliver accurate
cancer structural aberration map for all these samples. From this large-scale genome data
analysis, we gain knowledge on the genomic structural forces in tumorigenesis and reveal
mechanisms in cancer genome amplifications.
4.2 Methods
4.2.1 Data preparation
We require > 15X tumor haplotype coverage to be su cient for SVs analysis using Weaver.
Determining tumor haplotype coverage from WGS data on primary tumor sample is non-
trivial and part of the analysis pipeline we are developing, the WGS aligned BAM files of 635
samples across 21 tumor types were downloaded from CGHub (https://cghub.ucsc.edu/)
because there are > 470 million 100bp paired-end reads aligned, which is the number of
aligned paired-end reads leading to at least 15X tumor haplotype level coverage, when no
aneuploidy or normal cell content exists. After estimating the actual tumor haplotype
coverage using Weaver, 600 of 635 samples (tumor type numbers deceased from 21 to 17)
were retained in this study satisfying following criteria: i) read length   100bp; ii) Minor
Allele Frequency (MAF) and coverage should have at least two clusters (as illustrated in
Figure 10 and details in Chapter 2) that normal and tumor haplotype level coverage can
be estimated; iii) the estimated tumor haplotype coverage should be higher than 15X.
All mutation, expression and survival data for these 600 samples were obtained from
CBioPortal (Cerami et al., 2012). The workflow of data preparation of pan-cancer analysis
is in Figure 35.
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4.2.2 Identifying recurrent focal amplifications
We screened whole genome region with 1Mbp fixed size windows and if a window has been
amplified to absolute copy number > 6 (leading to approximately top 1% most amplified
1Mbp windows) and the size of the entire amplified region by combining nearby amplified
windows is < 10Mbp, the window will be labeled as focal amplification. We merged all
adjacent 1Mbp windows which have been focally amplified by   5 unique TCGA samples
(  1% all samples) and identified 17 merged regions as recurrent focal amplicons, where
  12 unique TCGA samples (  2% all samples) have focal amplifications.
4.3 Results
4.3.1 Most of SCNAs are caused by genome SVs
Across 600 samples, 82.3% SCNAs have exact boundaries (with base-pair resolution, method
described in Chapter 2) detected as SVs from our Weaver analysis. The high accordance
rate of SCNA boundaries with SVs shows that most of SCNAs are caused by genome struc-
ture alterations, and serves as the incentive for Weaver method that combines the SCNA
and SV analysis. Indeed, the accordance between SCNA boundaries and SV breakpoints has
also been reported by a study on iAMP21 ALL patients (Li et al., 2014), demonstrating that
several recurrent cancer-specific mutational processes can coordinate to shape copy-number
profiles over large genomic scales, incrementally refining the fitness benefits of aggregated
gene dosage changes. We will specifically investigate the various recurrent SV patterns that
lead to recurrent copy number amplifications in the following sections.
We note that arm level deletions or amplifications might have breakpoints within highly
repetitive regions or centromeres, making the detection of associated SVs impossible given
the read length of analyzed TCGA WGS samples, partially explaining the missing part of
the consistency between SCNA boundaries and SV breakpoints.
4.3.2 Landscape of SVs in cancer genomes
With Weaver, we identified 40,282 SVs for 600 TCGA WGS samples. The distribution of
number of SVs across di↵erent tumor types are presented in Figure 36. We also plotted
the distribution of di↵erent types of SVs across chromosomes (Figure 41). Deletions and
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TDs overlap 90% with germline DGV (MacDonald et al., 2014) are excluded from current
analysis. The distances between two breakpoints of deletions and TDs are < 1Mbp; the
distances between two breakpoints of FBIs are< 50kbp. All remaining INTRA chromosomal
SVs are labeled as INTRA while INTER chromosomal SVs are labeled as INTER. The most
rearranged chromosomes are chr19 and chr17 (Figure 41).
With allele specific copy number of SVs (ASCNS) characterized, we observed that (de-
tails in Figure 42) the percentage of INTRA chromosomal increases as ASCNG gets higher,
potentially from the contribution of chromothripsis which usually involves highly amplified
INTRA chromosomal SVs. We also observed that portion of BFB increases as the ASCNG
grows, which can be explained by existence of multiple rounds of amplifications during the
BFB cycles.
Cancer genome structural alterations tend to be clustered around important tumor sup-
pressors or oncogenes, or common fragile sites that show increased rates of DNA breakage
in normal cells in response to agents causing replicative stress (Bignell et al., 2010; Lukusa
and Fryns, 2008; McClintock, 1942). We segmented whole genome into 1Mbp bins and the
number of patients with at least one SV breakpoint within each bin was calculated. Bins
with at least 25 patients, or with at least 20 patients and there exists an adjacent bin with
at least 25 patients, are plotted in Figure 40, with color coded for di↵erent types of SVs.
In total, we selected 139 1Mbp regions with high SV breakpoint density and 47 clusters are
found if we merge 1Mbps bin within 2Mbp range. Chromosome 18, 21, X and Y have no
significant focal SV clusters.
LRP1B, FHIT, CCSER1, PDE4D, PARK2, IMMP2L, CDKN2A, PTEN, GPHN, RB-
FOX1, WWOX and MACROD2 are featured with frequent deletions and these focal dele-
tions are major components in SV clusters. It has been reported that gene FHIT and
WWOX are on known chromosome fragile sites FRA3B and FRA16D (Iliopoulos et al.,
2006; Huebner and Croce, 2001).
Although most of genes disrupted in SV clusters are due to recurrent deletions, we
found that, the dysregulation of THSD4 (involved in ECM assembly) ,within a SV cluster
on chromosome 15 is primarily from TD of its internal exons, instead of deletions. One
previous analysis on breast cancer cell lines has also confirmed one case with exons 6 and 7
of THSD4 duplicated (McBride et al., 2012).
All 17 recurrent focal amplifications were also found to be within high density struc-
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turally varied regions with details illustrated in Figure 39. The focal amplification region
13q22.3, containing intestinal-enriched kruppel-like factor (KLF5), a positive regulator of
cellular proliferation and transformation (Nandan et al., 2004), is frequently observed in
COAD (Martin et al., 2007). The amplification on 17q23 has been widely observed in
BRCA (Monni et al., 2001) and other cancer types (Ried et al., 1994; Weber et al., 1997)
(Figure 52).
4.3.3 Frequent translocations in cancer genome
Many frequently amplified regions in di↵erent tumor types have been reported to be un-
dergone frequent co-amplification. For example in GBM, multiple receptor tyrosine kinases
(RTKs), including EGFR and PDGFRA, are co-activated (co-amplified) and the redundancy
thereby limits the e cacy of therapies targeting any single RTK. It has been reported that
Anti-PDGFR therapy has failed in GBM patients (Wen et al., 2006), and only 10⇠20% of
patients benefit from EGFR inhibition (Rich et al., 2004).
Most of previous co-amplification analysis are based on indirect inference from array
data. WGS provides the opportunity to directly investigate the co-amplification or in general
the frequent translocations in cancer genome.
We have identified that, the most frequent translocations are on chr17 and chr12 (Ta-
ble 5), both showing tumor type specificity. There are two clusters of translocations on
chr17, 17q11.2⇠ERBB2 and ERBB2⇠17q21.3, both harboring ERBB2 amplicons (several
instances are plotted in Figure 53). Note that (Inaki et al., 2014) also reported the fre-
quent translocations of ERBB2⇠17q21.3. Given that the genomic coordinate of BRCA1
gene is between ERBB2 and 17q21.3, and will be skipped when ERBB2 is translocated to-
gether with 17q21.3, Inaki et al. (2014) proposed that this translocation is the topologically
parsimonious strategy to generate a genomic state favoring tumor growth, by co-amplifying
ERBB2 and 17q21.3. By pulling all ASCN results together for BRCA patients on chr17
(Figure 52), it is clear that BRCA1 resides in the copy number ‘valley’ formed by ampli-
fication of ERBB2 and 17q21.3 (as well as 17q23).
The translocation cluster on chr12 harbors two genes that have frequently been fo-
cally amplified: CDK4 and MDM2 (21 out of 600 samples). Four GBM samples with
this translocation are plotted in Figure 57. CDK4-MDM2 co-amplification is observed in
both retroperitoneal and peripheral well-di↵erentiated liposarcoma (ALT/WDLPS) (Dei Tos
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et al., 2000) and used as diagnose marker (Sirvent et al., 2007). CDK4-MDM2 co-amplification
has also been reported to be frequently event in other tumor types, including GBM (Schmidt
et al., 1994; Reifenberger et al., 1994; Zack et al., 2013), LIHC (Edamoto et al., 2003),
melanoma (Muthusamy et al., 2006), sarcomas (Khatib et al., 1993) and bladder cancer (Si-
mon et al., 2002). In this study, we observed that the majority of the CDK4-MDM2 translo-
cation (Table 5) and the majority of CDK4-MDM2 amplification (Figure 39) are all from
GBM.
4.3.4 Recurrent focal amplifications are generated from varied
mechanisms
Gene amplification is a common defect in cancer genome. Amplification in specific amplicons
has importance for both prognosis and targeted therapies (Albertson, 2006). Of 17 recurrent
focal amplicons detected in our PAN-cancer analysis, MYC, ERBB2, CCND1, EGFR and
MDM2 focal amplifications have been reported to be individually significantly associated
with the decreasing survival in BRCA (Albertson, 2006; Blegen et al., 2003).
TD and BFB (Campbell et al., 2010) are two mechanisms for focal amplifications. We
observed enrichment of specific tumor type or amplification mechanisms for di↵erent recur-
rent focal amplicons. The detailed distributions of number of samples from each tumor type
on 17 recurrent focal amplicons from TD or BFB are shown in Figure 39.
1. TD: Despite being a common class of SVs in various tumor types (Stephens et al.,
2009; Basecke et al., 2006; Jones et al., 2008), TD has previously been overlooked
since they involve small chromosomal segments beyond the resolution of cytogenetics
or copy number arrays. Amplifications on EGFR, PDGFRA, CDK4 are primarily
generated from TD of GBM samples. Large fraction of LIHC, UCEC, STAD and OV
patients have amplifications formed by TD (Table 4). The detailed example of TD
is illustrated in Figure 50(A).
2. BFB: Previous studies have proposed ‘firestorms’ model (Hicks et al., 2006), instead
of TD model, of the amplifications in cancer genome, within which clustered narrow
peaks of elevated copy number are observed. Telomere dysfunction is a major part in
BFB cycles (Maser and DePinho, 2002). Incorrect repair between broken telomeres
can result in the formation of dicentric chromosomes and the creation of BFB cy-
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cles (van Steensel et al., 1998). The BFB procedure is illustrated in Figure 2. With
base-pair resolution SV and ASCN detected from WGS data, we are able to investi-
gate more details of the complex amplifications. We have found that these clustered
peaks are likely to be outcome of BFB cycles (Zakov et al., 2013) since strong FBI
signals are always observed in nearby regions. FBI is a common type of copy number
variations been observed in both germline and somatic (Hermetz et al., 2014) and
most important feature in identifying BFB (Zakov et al., 2013). FBIs have spacer
between the two inversion breakpoints (Hermetz et al., 2014) and the distribution
between two breakpoints of FBI is plotted in Figure 51. The detailed example of
BFB is illustrated in Figure 50(B).
DNA copy number analysis of BRCA has identified enriched SCNA on chr17, especially
around ERBB2 (Przybytkowski et al., 2014). ERBB2 amplification is frequently co-occurred
with 17q21.3 amplification in BRCA samples, as reported by a study based on di↵erent
BRCA samples (Inaki et al., 2014). However, only three out of 12 ERBB2 focally amplified
BRCA samples were formed by TD, while (Inaki et al., 2014) reported that most of the
ERBB2 amplifications in BRCA are TDs, potentially because they did not search for FBIs.
Interestingly, on the contrary to observations in BRCA, both ERBB2 focally amplified OV
samples are indeed from TD. In ERBB2 amplified STAD samples, three out of five have
chromothripsis and the piece of genome with ERBB2 retained in derived cancer chromosome.
In UCEC, 4 out of 5 samples are TD and only one sample show feature of BFB on ERBB2
amplicons. Although HNSC and LUSC shares similar SCNA patterns (Hoadley et al., 2014),
ERBB2 is more amplified in HNSC samples (6 out of 42 in HNSC vs. 1 out of 48 in LUSC).
Overall, ERBB2 amplicons are primarily generated from BFB. Since ERBB2 amplifications
leads to Her2 over-expression, most of BRCA samples in BFB subtype are classified as Her2-
enriched in PAM50 model (Parker et al., 2009). Detailed rearrangement plot of ERBB2is
in Figure 53.
EGFR, PDGFRA, CDK4 and MDM2 amplifications are significantly found in GBM
samples (Verhaak et al., 2010; Schmidt et al., 1994; Reifenberger et al., 1994; Edamoto
et al., 2003). From our analysis, most of amplifications for these genes are from TD (details
in Figure 39), consistent with previous report by Yang et al. (2013a) on EGFR. Detailed
rearrangement plot of EGFR is in Figure 55.
In both LUSC and HNSC samples, BFB is the major mechanism that leads to focal
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amplifications in CCND1 and CCNE1. 11q13.3, including CCND1, has been reported to be
significantly amplified in previous analysis in OV (Cancer Genome Atlas Research Network
et al., 2011), LIHC (Guichard et al., 2012; Sawey et al., 2011) and Oral Squamous Cell
Carcinoma (OSCC) (Shuster et al., 2000). Especially more than half of OSCC samples have
CCND1 amplification generated by BFB (Shuster et al., 2000). CCND1 over-expression can
lead to premature cell cycling through the G1/S transition, resulting in propagation of unre-
paired DNA damage and accumulation of genetic errors. It has been reported that CCND1
focal amplification might be associated with common fragile sites FRA11A at 11q13.3 and
FRA11F at 11q14.2 (Bieche et al., 2002). Only in HNSC, translocations between CCND1
and another frequently amplified region, 11q22, have been observed in multiple samples.
Detailed rearrangement plot for CCND1 is in Figure 54.
Human telomerase gene (TERC), PIK3CA and transcription factor gene SOX2 are all on
3q26, which is frequently amplified in di↵erent cancer types, including CESC (Heselmeyer-
Haddad et al., 2003, 2005) and LUSC (Yokoi et al., 2003). 3q26 is also negative prognostic
factor in HNSC (Singh et al., 2002). PIK3CA serves as an oncogene in CESC (Ma et al.,
2000). SOX2 plays key role in development of LUSC (McCaughan et al., 2010), especially
serving as a lineage-survival oncogene (Bass et al., 2009). We plot the examples of de-
tailed TERC-PIK3CA-SOX2 focal amplifications in Figure 59. According to observations
in Figure 39, nearly all LUSC and HNSC samples focally amplified in this region were
amplified from BFB mechanism, while OV, LIHC, UCEC samples are primarily amplified
by TD on this region.
4.3.5 Classify tumor genome according to SV features
Motivated by the dramatic di↵erence in mechanisms of recurrent focal amplifications on
pan-cancer scale, we classify TCGA samples we analyzed with di↵erent tumor types into
subtypes according to their SV features with following steps:
1. BFB: According to the definition of BFB (Hicks et al., 2006; Zakov et al., 2013)
and previous experimental analysis of tumor samples with BFB (Reshmi et al., 2007;
Kitada and Yamasaki, 2008), FBI, together with copy number profiles, is reliable
indicator of BFBs (Zakov et al., 2013). Here we classify a sample into BFB with two
steps: i) when the sample has BFB on at least one of 17 recurrent focal amplicons,
if the occurrence of BFB > TD on 17 recurrent focal amplicons or BFB = TD but
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overall counts of FBI   TD, the sample will be classified as BFB subtype. The BFB
subtype samples selected in this process has third quartile minimum number of FBI
as 20. ii) when the sample has no BFB or TD on any of 17 recurrent focal amplicons,
if the counts of FBI   20 and   TD counts, the sample will also be classified as BFB.
LUSC (70.8%), HNSC (57.1%), CESC (50%), OV (48.9%) and BRCA (39%) have
their largest fraction in BFB subtype.
2. TD: Tandem Duplication (TD) is another well known source of focal amplifications.
Here we classify a sample into TD with two steps: i) when the sample has TD on
at least one of 17 recurrent focal amplicons, if the occurrence of TD > BFB on 17
recurrent focal amplicons or TD = BFB but overall counts of TD > FBI, the sample
will be classified as TD subtype. The TD subtype samples selected in this process has
third quartile minimum number of TD as 21. ii) when the sample has no TD on any
of 17 recurrent focal amplicons, if the counts of TD   21 and > counts of FBI, the
sample will also be classified as TD. GBM (70.7%), UCEC (47.1%), LUAD (38.1%)
and STAD (34.5%) have their largest fraction in TD subtype.
3. STABLE: Tumor genomes have less than 20 SVs and no aneuploidy has been observed
are defined as STABLE subtype. 23.7% of all samples are classified as STABLE.
The majority of STABLE samples are OTHER (KICH (76%), KIRC (57.9%), KIRP
(47.4%), THCA (65.7%), PRAD (66.7%)).
4. MINOR: Tumor genomes with modest rate of SVs (less than 100) and no BFB or
TD patterns observed are defined as MINOR subtype. 25.2% samples are classified
as MINOR subtype. Most of COAD/READ (50.9%) and LIHC (40.7%) samples fall
into this subtype.
5. CHROMOTHRIPSIS: Recent study showed that DNA damage in micronuclei
might lead to chromothripsis (Zhang et al., 2015). The two most commonly used
evidence for identifying chromothripsis is high density of SVs, with evenly distributed
head/tail orientations, and the oscillating copy numbers (Korbel and Campbell, 2013).
Incorporating metrics proposed by the previous pan-cancer SCNA study (Zack et al.,
2013), which was solely based on copy number, we set the criteria to call chromothrip-
sis as: i) elevated rate of long range (>5Mbps) INTRA chromosomal SVs or INTER
chromosomal SVs. This requirement filters out SCNAs caused by BFB since FBIs have
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small sizes; ii) At least 10 of the SVs share the same copy number (when copy number
of SVs are higher than ten, +/   1 in copy number is tolerated since the absolute
copy number of SVs are hard to quantify when the copy number is high). Note that
this requirement is equivalent to ‘oscillating’ SCNAs defined in Korbel and Campbell
(2013); iii) We set the upper limit of number of chromosomes involved in chromoth-
ripsis as four since multi-chromosomal CHROMOTHRIPSIS is rare. No tumor types
have their major fractions allocated into this subtype. Overall, 4.7% samples are clas-
sified as CHROMOTHRIPSIS. We use CRM as abbreviation of CHROMOTHRIPSIS
subtype in figures.
The percentage of each tumor type classified into each SV subtype is summarized in
Table 4. Detailed distribution of two amplification mechanisms for 17 focal amplifications,
tumor types, SV types and SV subtypes are summarized in Figure 43 for all 600 samples.
To test if our classification is sensitive to our selection of top recurrently focal amplified
regions, we performed the classification on top 15 to 19 most frequently amplified regions
and the classification di↵erence is <3% comparing with current classification based on 17
regions, which was selected by setting the minimum fraction of patients been amplified as
2%.
The distribution of di↵erent types of SV in five subtypes are summarized in Figure 44.
STABLE and MINOR samples have much lower level of SVs comparing with other three
subtypes. BFB and TD are enriched with FBIs and TDs, respectively. CHROMOTHRIPSIS
samples have elevated rate of INTRA chromosomal SVs, which is consistent with the feature
of chromothripsis that a segment of or whole chromosome was shattered into pieces and
rearranged, leading to enrichment of INTRA chromosomal SVs.
Map of functional or actionable alterations, including homozygous deletions, focal ampli-
fications and mutations, across five SV subtypes is illustrated in Figure 46. The STABLE
subtype has no functional alterations higher than 10%, while all other four types have en-
richments in certain alterations. STABLE has the highest mutation rates for BRAF and
KRAS, both in MAPK signaling pathways. Although the level of alteration is still low in
MINOR, when compared with STABLE, the MINOR subtypes have much higher muta-
tion rate of TP53 and amplification of key genes in transcription factor/regulator, PI(3)K
signaling and Wnt/ -catenin signaling pathways.
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BFB, TD and CHROMOTHRIPSIS subtypes have much higher rate of SVs, as well as
functional alterations. In cell cycle pathway, BFB has the highest rate of CCND1, CDK12
and CCNE1 amplifications, and highest rate of CDKN2A mutation. On the contrary, TD
subtype alters the cell cycle pathway through the amplification of CDK4 and homozygous
deletion of CDKN2A and only 1% CDKN2A mutation has been found in TD samples. BFB
alters the RTK signaling pathway through enrichment of ERBB2 amplifications, while TD
has KIT, EGFR and PDGFRA significantly amplified.
4.3.6 Classification of tumor genomes with SV implies di↵erent
prognosis
Figure 47 shows the corresponding survival plot for the classifications. Median survival
was estimated using the Kaplan-Meier method (Kaplan and Meier, 1958; Rich et al., 2010)
and the di↵erence was tested using the log-rank test. We have observed that, the survival of
patients across di↵erent tumor types get worse from SV subtype STABLE, MINOR, BFB,
TD to CHROMOTHRIPSIS. The most interesting finding is that di↵erent focal amplifica-
tion mechanisms, BFB and TD, have di↵erent prognosis potential that even from the same
tumor histological type, BFB patients have better survival than TD patients (as KM plot for
OV patients in Figure 48(A)). Comparing the gene expression for OV patients across BFB
and TD subtypes, we have found five genes di↵erentially expressed (t-test, q-value < 0.1),
including WT1, EHF and MYC, which are all reported to be important genes in cell devel-
opment and carcinogenesis (Kleinbaum et al., 1999; Oka et al., 2004; Albino et al., 2012).
We studied all TCGA samples used in this study, excluding OV patients, to investigate
whether the overall trend of better survival by BFB subtype is biased by over representa-
tion of OV samples. As in Figure 48(B), the conclusion still holds. Although BRCA has
large number of patients in both BFB and TD subtypes, the low death rate (5/37) makes
the sample size insu cient for survival comparison of subtypes in BRCA patient samples.
4.3.7 Relation between SV with replication timing and Hi-C
SCNA has been revealed to, at least partially, originate from 3D proximity of genomic
regions which are distal in 2D (De and Michor, 2011). It is been revealed that genomic
translocations are highly associated with proximity (Roukos and Misteli, 2014; Zhang et al.,
2012) and proximally positioned chromosomes in 3D undergo translocations at higher fre-
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quencies than distal chromosomes (Roukos et al., 2013). De and Michor (2011) analyzed
pairs of boundaries from each SCNA and discovered that two boundaries of the same SCNA
tend to be originated from regions with similar replication timing. One drawback of the
analysis is that SCNAs have di↵erent mechanisms and we have found that a significant
portion of SCNAs are formed by FBI and under such circumstance, the assumption that
two boundaries of SCNA are proximal in 3D does not hold anymore (two FBI boundaries
are originated from two temporally sequential BFB cycles). With base-pair resolution SVs,
we can search for the replication timing di↵erence of distal breakpoints, including all types
of genomic alterations, not just SCNA. We obtained RepliSeq data from ENCODE (Hansen
et al., 2010). In order to remove the potential confounding impact from SCNAs in cancer cell
lines, we used normal cell line GM12878 in our analysis. As in Figure 61(A), the observed
di↵erence between a pair of breakpoints from a SV is less than expected, implying that SVs
tend to originate from regions with similar replication timing. The expected di↵erence was
calculated using simulated sets of SVs, which were randomly generated SVs with following
steps: i) for INTRA chromosomal SVs, simulation SVs are generated with the same size of
observed SVs; ii) for INTER chromosomal SVs, simulated SVs have breakpoints from the
same pair of chromosomes of observed SVs. We also utilized 1Mbp resolution data Hi-C
data from Rao et al. (2014) to analyze the relationship between SV breakpoints and their
3D configuration. For each pair of 1Mbp regions linked by TCGA SVs, we calculate the
number of Hi-C reads. As in Figure 61(B), the observed Hi-C read support is higher than
expected, which was generated by the same approach as in Repli-seq analysis.
4.4 Discussion
Our study provides the largest SV and base-pair resolution ASCNG analysis across tumor
types to date. One previous analysis (Yang et al., 2013a) on 140 cancer WGS data summa-
rized the base-level features of SV breakpoints, however, no integration analysis of ASCNG
and SV has been done. Using Weaver, we categorized the distribution of SVs across di↵erent
tumor types.
Loss of genomic integrity is common feature in cancer, with scale ranging from chro-
mothripsis (Stephens et al., 2011), kataegis (Nik-Zainal et al., 2012), BFB to aneuploidy.
Interestingly, although the di↵erence between genomic profiles of individual cancer genomes
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is dramatic for the most of time, strong recurrencies, either on focal or chromosome arm level,
have been observed when performing pan-cancer analysis. Recent analysis has reported that
across-sample copy number profile on chr21 can be generated by recurrent chromothripsis
in a specific subgroup of acute lymphoblastic leukemia patients (Li et al., 2014), suggesting
that recurrent ASCNG profiles are generated by recurrent SV mechanisms. This type of
study can never be made without deep WGS. Comparing with array data, WGS not only
delivers accurate identification of SCNAs, but also enables the interpretation of how SCNAs
are formed by SV.
The impact of SVs, especially recurrent ones that happen on same regions across tumors
with frequency higher than by chance, are revealed to be the foundation of forming of
recurrent SCNAs. We analyzed two mechanisms for recurrent focal amplifications and
found that di↵erent frequently focal amplified regions have di↵erent enrichment of specific
tumor types. We proposed a new cancer genome classification method, for the first time
utilizing SV pattern, that categorizes 600 TCGA samples across 17 tumor types into five
subtypes, including STABLE, MINOR, BFB, TD and CHROMOTHRIPSIS, with potential
clinical relevance. Our SV based classification has the potential of prognostic assessment
for future patients in several tumor types.
The major limitation of this study is the depth and width of available samples. Although
the overall sample size 600 is large, the sample size on each tumor type level is insu cient for
drawing more concrete conclusions. The current set of results is based on molecular profiles
from only 17 tumor types, all solid tumors, which are represented by sample numbers varying
from 12 to 56. The behavior of amplifications in hematological cancers are not investigated
in this study due to lack of high coverage hematological cancer WGS data. We believe
that understanding of tumor biology in terms of accurate genomic SVs will serve as an
unprecedented opportunity to be explored in the laboratory and in the clinic, with more
and more deep WGS data available, paving the path towards the development of precision
cancer therapies.
4.5 Figures and Tables
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Figure 35: Workflow of preparing data for pan-cancer analysis. We first download bam
files for both tumor and normal samples from CGHub using gtdownload (developed by
Sage Bionetworks) and then check the tumor bam file: if read length is <100bp or the
number of read pairs < 470 million, we discard the downloaded sample. We run Weaver
to estimate the haplotype coverage for tumor genome and we discard the sample if the
coverage is < 15X or unable to be inferred (as in Figure 10). We then run Weaver on all
600 remaining qualified samples and primarily generate ASCNG and ASCNS profiles for
each sample. Together with mutation, expression and survival data for these 600 samples
obtained from CBioPortal (Cerami et al., 2012), we perform the pan-cancer analysis.
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Figure 36: Distribution of gross SV numbers across tumor types from TCGA WGS data.
Since pan-cancer analysis of SVs is not available, we compare the distribution of SV num-
bers with the pan-cancer density of focal SCNAs reported by a previous study based on
array (Zack et al., 2013). Our result is consistent with previous analysis that BRCA, OV,
LUSC, UCEC and LUAD have high SV (SCNA) density, while KIRC and COAD have low
SV (SCNA) density.
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Figure 37: Distribution of sample purity across tumor types from TCGA WGS data. The
lower limit of normal cell fraction is 50% in current Weaver run.
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Figure 38: Distribution of sample ploidy across tumor types from TCGA WGS data. This
result is consistent with previous analysis that BRCA, OV, LUSC, LUAD and HNSC have
high ploidy, while GBM and KIRC have low ploidy (Zack et al., 2013).
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Figure 39: Distribution of frequently amplified region with di↵erent amplification mech-
anisms. For each frequently amplified region, two stacked bar plots of BFB (left) and TD
(right) represent the (A) absolute number (B) percentage of TCGA samples amplified with
the corresponding mechanism. For example, LUSC has 11 samples have focal amplification
on CCND1 with BFB and no sample with TD. From the observation on 17 recurrently focal
amplicons, GBM, CESC, STAD and LIHC samples are more likely be amplified from TD;
HNSC and LUSC samples are more likely to be amplified from BFB. OV and BRCA samples
did not show clear bias towards the two mechanisms. This observation is consistent with
Table 4. The detailed browser plot for ERBB2, CCND1, EGFR, CCNE1, CDK4-MDM2,
PDGFRA, TERC:PIK3CA:SOX2 and 11q22 focal amplifications with SVs annotated are in
Figure 53, Figure 54, Figure 55, Figure 56, Figure 57, Figure 58, Figure 59 and
Figure 60.
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Figure 40: SV density pattern from 600 TCGA patients across di↵erent chromosomes. The
X-axis represents genomic coordinates and the Y-axis represents the absolute number of SVs
for each 1Mb window. The SV type in each bin are color coded. Genes/regions amplified
or deleted are illustrated with red or blue. Regions enriched with INTRA or INTER SVs
are labeled with their chromosomal coordinates.
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Figure 41: Distribution of SVs across di↵erent chromosomes normalized by corresponding
chromosome sizes. Y axis shows the number of SVs every 1Mbp. Chromosome 17 and 19
have the highest density of SVs. SVs on Y-chromosome are not investigated in this study.
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Figure 42: Relative percentage of di↵erent types of SVs with di↵erent ASCNS, on X axis,
are shown on Y axis. Absolute numbers of all SVs with specific ASCNS are annotated on
top of stacked bars. It is shown on the plot that INTER chromosomal SVs have stable
percentage across all ASCNS. The percentage of INTRA chromosomal increases as ASCNG
gets higher, potentially from the contribution of chromothripsis which usually involves highly
amplified INTRA chromosomal SVs. We also observed that portion of BFB increases as the
ASCNG grows, which can be explained by existence of multiple rounds of amplifications
during the BFB cycles.
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Figure 44: Distribution of SVs across di↵erent SV subtypes. Y axis shows the medium
number of di↵erent SV types. As expected, BFB and TD subtypes are enriched with FBI
and TD, respectively. Samples in CHROMOTHRIPSIS subtype are enriched with INTRA
chromosomal translocations, which is one of key features of chromothripsis.
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Figure 45: Distribution of aneuploidy with di↵erent allele ratios on each autosome across
five SV subtypes. Y axis shows the mean percentage of genome that are aneuploid with
specific allele ratio. Normal diploid allele ratio 1:1 is omitted in this plot and the stacked
bar can be viewed as the gross percentage of aneuploidy. X axis shows autosomes. STA-
BLE tumors have the lowest aneuploidy rate comparing with other four subtypes. TD has
lower degree of aneuploidy than BFB, potentially because BFB and aneuploid share similar
formation mechanism, telomere crisis. CHROMOTHRIPSIS has highest rate of high CN,
which is consistent with observation in chromothripsis cancer genome. Overall, 2:1 is the
most frequent allele ratio in aneuploid cancer genome.
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Figure 46: Map of functional or actionable alterations across five SV subtypes. Number
in each box shows the detailed percentage of homozygous deletions, focal amplifications
or mutations for each SV subtype. Focal amplifications are illustrated with red (elevating
the gene’s function) while homozygous deletions and mutations are illustrated with blue
(inactivating the gene’s function). The gene list with important pathways were retrieved
from two previous pan-cancer studies (Ciriello et al., 2013; Kandoth et al., 2013) and only
those genes altered in at least 5% of any SV subtype were plotted.
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Figure 47: Kaplan-Meier plot of SV subtypes. The plot was generated by using Lifelines
python package (Davidson-Pilon, 2015).
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Figure 48: Kaplan-Meier plot of BFB and TD subtypes of OV and OV excluded samples.
The number of patients are annotated for each subtype. (A) OV patients in BFB subtype
have better survival than those in TD subtype (log rank test P-value < 0.001). (B) When
OV patients are excluded, the overall trend that Pan-cancer BFB patients have better
survival than TD patients remains the same (log rank test P-value < 0.001).
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Figure 49: Kaplan-Meier plot of two SV subtypes, MINOR and BFB, for HNSC patients.
Since the majority of HNSC patients included in this study falls into MINOR and BFB
subtypes, survival di↵erence between MINOR and BFB (log rank test P-value < 0.05)
demonstrated the power SV classification.
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TD 11p15.4 15.2 11p15.1 p14.3 p14.1 11p13 11p12 11p11.2 11 q12.1 q13.4 11q14.1 q14.3 11q21 q22.1 11q22.3 11q23.3 q24.2 24.3 11q25chr11
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53 copies
Figure 50: TD and BFB examples. (A) An example of focal CCND1 amplification formed
by TD. The green allele has one copy and independent from the amplification, while purple
allele has been amplified to ⇠53 copies and the link between two amplified copy shows
TD, that tail-head linkage (purple lines) is detected by NGS. Similarly, an example of
focal CCND1 amplification formed by BFB is illustrated in (B). The green allele has been
amplified to three copies and independent from the amplification, while purple allele has
been amplified to ⇠72 copies and the link between two amplified copy shows BFB (FBI),
that tail-tail/head-head linkage (red arrows with di↵erent orientations) is detected by NGS.
The same notation will be used in screen shot plots for Figure 53, Figure 54, Figure 55,
Figure 56, Figure 57, Figure 58, Figure 59 and Figure 60.
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Figure 51: Size distribution of two breakpoints of FBI. Except for those with distance
> 10kb, majority of FBI have breakpoints < 1kb.
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Figure 52: The overall copy number profile across 59 BRCA samples on chr17.
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Figure 53: Screen shots from UCSC genome browser for ERBB2 focal amplification exam-
ples are displayed. As described in Figure 50, red arrows show the position and orientation
of FBI and purple lines show TD. The TCGA barcode name is color coded to orange or
purple if ERBB2 gene is amplified through BFB or TD, respectively. Blue lines, linking
distal regions on chromosome, show INTRA chromosomal translocations. There are some
half blue lines, in which case the translocation partner is outside the entire plotting region.
INTER chromosomal SVs are marked with the detailed chromosomal coordinate of the
breakpoint. If INTRA chromosomal SVs are found between two SV clusters listed in Fig-
ure 40, the co-amplified clusters are highlighted in blue color under corresponding TCGA
barcode name. The plot is not comprehensively displaying all ERBB2 focal amplifications.
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Figure 54: Examples of CCND1 focal amplifications with figure annotations same as in
Figure 53. CCND1 amplification is predominantly formed by BFB cycles and featured
with FBIs.
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Figure 55: Examples of EGFR focal amplifications with figure annotations same as in
Figure 53. Interestingly, the EGFR TD amplifications on three GBM patients: TCGA-06-
0152, TCGA-06-0157 and TCGA-19-2620, are not directly formed, but by linking to other
genomic regions. For example in TCGA-06-0152, the oncogene MDM4 (Riemenschneider
et al., 1999) is part of the TD and co-amplified.
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Figure 56: Examples of CCNE1 focal amplifications with figure annotations same as in
Figure 53. UCEC focal amplifications on CCNE1 are primarily (4 out of 5) formed by
BFB while CCNE1 focal amplifications in OV samples are more likely (7 out of 10) to be
formed by TD.
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Figure 57: Examples of CDK4 and MDM2 focal amplifications with figure annotations
same as in Figure 53. CDK4 and MDM2 amplifications are predominantly formed
by TD. INTRA chromosomal translocations linking CDK4 and MDM2 are plotted for
GBM:TGCA-06-0686, GBM:TCGA-19-2624, GBM:TCGA-26-5135, GBM:TCGA-06-0152
and LUAD:TGCA-55-6982.
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Figure 58: Examples of PDGFRA focal amplifications with figure annotations same as
in Figure 53. 8 of 41 GBM samples analyzed in this study have focal amplifications on
PDGFRA gene and all of them are formed by TD.
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Figure 59: Examples of TERC-PIK3CA-SOX2 focal amplifications with figure annotations
same as in Figure 53. TERC-PIK3CA-SOX2 focal amplifications span across large fraction
of long arm of chr3.
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Figure 60: Examples of 11q22 focal amplifications with figure annotations same as in
Figure 53. BFB is the dominant mechanism (6 out of 6) for 11q22 focal amplification in
CESC. 11q22 focal amplifications on HNSC were shown in Figure 54 since frequent INTRA
chromosomal SVs linking CCND1 and 11q22 are observed.
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Figure 61: Associating SVs with Replication timing and genome 3D structure by HiC. (A)
Distributions of replication di↵erence for observed SVs and expected SVs by simulation are
plotted. P-value from Kolmogorov-Smirnov test is 2.582e 52. Showing that two boundaries
of observed SVs share significantly close replication timing than expected. (B) Distribu-
tions of number of INTER chromosomal Hi-C reads for observed SVs and expected SVs by
simulation are plotted. P-value from Kolmogorov-Smirnov test is 1.325e 80, showing that
Hi-C interaction on observed SVs is significantly higher than expected.
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Table 4: Numbers of TCGA deep WGS samples available for Weaver analysis are listed
with abbreviations. Absolute number and fraction (percentage) of samples for each of five
SV subtypes are also shown. Any percentage higher than 20% are highlighted
STABLE MINOR BFB TD CHROMOTHRIPSIS Overall
LUSC 3/6.2 4/8.3 34/70.8 5/10.4 2/4.2 48
HNSC 4/9.5 12/28.6 24/57.1 2/4.8 0/0.0 42
OV 1/2.2 4/8.9 22/48.9 15/33.3 3/6.7 45
BRCA 5/8.5 9/15.3 23/39.0 14/23.7 8/13.6 59
LIHC 7/13.0 22/40.7 8/14.8 12/22.2 5/9.3 54
GBM 3/7.3 6/14.6 1/2.4 29/70.7 2/4.9 41
UCEC 3/8.8 10/29.4 5/14.7 16/47.1 0/0.0 34
STAD 3/10.3 9/31.0 7/24.1 10/34.5 0/0.0 29
LUAD 4/19.0 5/23.8 4/19.0 8/38.1 0/0.0 21
CESC 2/10.0 5/25.0 10/50.0 3/15.0 0/0.0 20
COAD 6/15.8 21/55.3 6/15.8 4/10.5 1/2.6 38
READ 3/20.0 6/40.0 2/13.3 3/20.0 1/6.7 15
KICH 38/76.0 6/12.0 2/4.0 1/2.0 3/6.0 50
PRAD 8/66.7 4/33.3 0/0.0 0/0.0 0/0.0 12
THCA 23/65.7 11/31.4 0/0.0 1/2.9 0/0.0 35
KIRC 11/57.9 3/15.8 2/10.5 1/5.3 2/10.5 19
KIRP 18/47.4 14/36.8 4/10.5 1/2.6 1/2.6 38
ALL 142/23.7 151/25.2 154/25.7 125/20.8 28/4.7 600
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Table 5: Frequent translocations in 600 TCGA samples
Regions Tumor samples
17q11.2 (17:28-33M) ⇠ ERBB2 (17:37M) BRCA:10 Total:12
ERBB2 (17:37M) ⇠ 17q21.3 (17:44-50M) BRCA:8 Total:8
CDK4 (12:58M) ⇠ MDM2 (12:69M ) GBM:4 Total:5
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Chapter 5
Conclusions
5.1 Summary of the thesis
With the rapid development of high-throughput NGS technologies, the cost of WGS has
been greatly decreased, urging the methodological developments that meet the scale and
complexity of the data generated. Especially in cancer genomes, which have the common
feature of loss of genomic integrity, leading to widespread SVs and SCNAs. The complexity
of highly rearranged cancer genome imposes significant computational challenges. Although
SVs and SCNAs have been separately characterized comprehensively in various tumor types,
no analysis has been performed on the interactions between them. Recent analysis has
reported that across-sample copy number profile on chr21 can be generated by recurrent
chromothripsis in a rare subgroup of acute lymphoblastic leukemia patients (Li et al., 2014),
suggesting that recurrent SCNA profiles are generated by recurrent SV mechanisms with
specific prognostic implications. Comparing with array method, WGS not only delivers
accurate identification of SCNAs, but also enables the interpretation of how SCNAs are
formed by global behavior of SVs. This thesis aims at building the missing bridge between
SV and SCNA analysis in cancer genome, by proposing a novel computational method
tackling challenges in cancer WGS and applying the method on both cell lines and primary
tumor sequencing data.
In this thesis, we developed a probabilistic graphical model, Weaver, that for the first
time combines the analysis of SVs and SCNAs in aneuploid cancer genomes. Being a SV-
centric integrative graphical model which well fits the complex nature of cancer genomes
with reorganized chromosomes, Weaver provides, for the first time, a quantitative measure-
ment of copy number of SVs in cancer genome and the phasing/linkage relationship between
them. Although there exist many ASCNG methods, however, Weaver is the first method
which generates the base-pair resolution ASCNG profile in aneuploid cancer genomes. Our
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simulation evaluation and real data application on MCF-7, HeLa, and TCGA data demon-
strated that Weaver is highly accurate and can significantly refine the analysis of complex
cancer genomes.
We generated lists of SVs with base-pair resolution and provided the first ASCNS and
ASCNG map for MCF-7 and HeLa. We believe the ASCNS/ASCNG map will serve as high-
quality cancer reference genomes for past and future experiments relying on these cell lines.
We have also discovered that a large portion of promoter-promoter interactions, detected
by ChIA-PET, are found to be formed by distal genomic regions linked to be adjacent by
somatic translocations in MCF-7 genome, showing that phased SVs analysis by Weaver has
enabled the analysis of interaction between genomic rearrangements and long-range gene
regulation at much broader scale.
We downloaded and analyzed 600 WGS samples from TCGA with tumor haploid cov-
erage >15X using Weaver. This analysis provides the largest SV profiling and base-pair
resolution ASCNS/ASCNG analysis across tumor types to date. We identified 47 clusters
of SV breakpoints in the pan-cancer analysis, with 12 and 23 of them are focal deletion and
amplification hotspots, while the remaining breakpoint clusters are enriched with translo-
cations. The impact of SVs, especially recurrent ones that happen on same regions across
tumors with frequency higher than by chance, are revealed to be the foundation of recurrent
SCNAs. We analyzed two mechanisms, BFB and TD, for recurrent focal amplifications and
found di↵erent frequently focal amplified regions have di↵erent enrichment of specific tumor
types. For example, CCND1 gene is primarily amplified by BFB mechanism, especially in
LUSC and HNSC; while EGFR gene is mostly amplified by TD, especially in GBM.
We proposed a new pan-cancer classification method, for the first time utilizing SV pat-
tern, that categorizes 600 TCGA samples across 17 tumor types into five subtypes, including
STABLE, MINOR, BFB, TD and CHROMOTHRIPSIS, with potential clinical relevance.
We discovered the survival decreases from STABLE subtype to CHROMOTHRIPSIS sub-
type, especially, TD has consistently worse survival than BFB, showing that di↵erent focal
amplification mechanisms are associated with di↵erent prognostic features. Although more
clinical investigations are needed, our pan-cancer classification has the potential of prognos-
tic assessment for future patients regardless of their tumor types.
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5.2 Limitations and future directions
Some aspects within this thesis could be further improved by future work. Although the
coverages of 600 TCGA WGS data used in this study are su cient for SV and SCNA analy-
sis, much higher coverages are need to confidently call somatic SNVs, thus somatic SNVs are
not investigated in this thesis. It is interesting to explore the relationship between the fea-
ture of SVs in cancer genome and behavior of somatic SNVs. For example, TP53 mutations
have been revealed to be highly correlated with SCNAs in various tumor types (Fridlyand
et al., 2006; Snijders et al., 2005). A previous study on HNSC showed that TP53 mutation
is frequently accompanied by loss of chromosome 3p and the combination of these events is
associated with a surprising decrease in survival time (Gross et al., 2014).
The presence of variant subclones within the cancer cell population, termed as intratu-
mor heterogeneity, is another feature of primary tumor genomes, and brought tremendous
challenges in bioinformatics analysis of tumor WGS data (Vogelstein et al., 2013). For
example, the existence of subclones in WGS data will confound the identification of SVs
and estimation of ASCNS/ASCNG. Studies have revealed subclonal changes across distinct
geographic regions of a primary tumor (Gerlinger et al., 2012) and within hematopoietic
malignant populations (Ding et al., 2012). A multiregion sequencing study on LUAD re-
vealed that a larger subclonal mutation fraction may be associated with increased likelihood
of postsurgical relapse in patients (Zhang et al., 2014). It has been proposed that the major
cause of genetic heterogeneity in cancer is genomic instability, including BFB (Gisselsson
et al., 2000), which leads to an increased mutation rate and can shape the evolution of the
cancer genome (Burrell et al., 2013). The development of single-cell sequencing technology
has accelerated studies of cancer heterogeneity (Navin et al., 2011; Eberwine et al., 2014;
Eirew et al., 2014). Single-cell sequencing is now providing cutting-edge clinical applica-
tions, especially in studying blood-borne circulating tumor cells (CTCs) (Heitzer et al., 2013;
Ni et al., 2013; Swennenhuis et al., 2013), derived from a solid tumor, to investigate the
value of CTCs for guiding diagnosis, prognosis, and treatment of the cancer. However, the
amount of DNA in single cell is not enough for current NGS technology and whole genome
amplification, which has inherent risk of inducing significant bias, is inevitable (Tre↵ et al.,
2011; Alix-Panabie`res and Pantel, 2014). Moreover, the isolation of single cell from tissues
and designing an optimal single-cell sampling strategy, which can comprehensively represent
the mutational landscapes within a primary tumor are both challenging (Eberwine et al.,
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2014). There are still pressing needs for building computational models which can tackle
the heterogeneity in primary tumor sequencing data.
Although the length is growing, NGS reads are still too short to cover larger or more
complex structural alterations, especially those with breakpoints inside centromere or other
low sequence complexity regions. Indeed, many arm-level SCNAs might have their break-
points right inside centromere gap regions and the SVs which formed these SCNAs would
inevitably be missed. Hybrid approaches that combine OM or ‘third generation sequenc-
ing’ provided by PacBio, together with NGS, might provide new insight into those genomic
regions hard to explore by current NGS technology alone.
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